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Alzheimer’s disease is the most common form of dementia and is considered to be caused by 
the conformational change of Aβ monomers, from their native monomeric states, to form Aβ 
oligomers/fibrils and affects the structure and function of neural cells leading to synaptic 
dysfunction. Recent experimental data elucidated that 12- crown-4 ether molecule can inhibit 
Aβ aggregation, reduce toxicity and disrupt the Aβ fibril structure, but the mechanism 
remains elusive. Various experimental studies have revealed that Aβ aggregate and fibrils 
interact with biological membranes, which lead to neuronal toxicity, especially cholesterol-
rich DPPC membrane; however, the mechanism of interaction remains unknown. To this end, 
I have performed several microseconds of all-atom molecular dynamics simulations of Aβ40 
and Aβ42 monomers, and Aβ40 trimer, in presence and absence of 12-crown-4 ether and 
coarse-grained simulations of the Aβ9-40 hexamer with the cholesterol-rich DPPC bilayer. 
  Simulations of Aβ40 and Aβ42 monomers with 12-crown-4 shows that the molecule 
is highly specific toward positively charged Lys residues and the region around Val24-Lys28 
is most prevalent for turn formation. Simulations data of Aβ fibrils trimer with 12-crown-4 
simulations reveals that it spontaneously, inserted into the hydrophobic core and opened the 
“U-shaped” topology of Aβ fibrils trimer and also disrupted Lys28-Asp23 salt bridge. Aβ 
fibrils hexamer with cholesterol-rich DPPC bilayer simulations reveals that Aβ fibrils 
hexamer spontaneously inserted to the mixed bilayer and hydrophobic residues played a key 
role in its binding, especially central hydrophobic cluster region (Lys16, Leu17, Val18, 
Phe19 and Phe20).  
 Results of Aβ monomers and Aβ fibrils trimer with 12-crown-4 ether reveals key 
pharmacophore features required in molecules to specifically bind with Aβ peptides. Data of 
Aβ fibrils hexamer reveals key pharmacophore features of Aβ protein to bind with the mixed 
lipid bilayer. The pharmacophore features identified in all the three studies will not only help 
in designing new candidate drug molecules, which are specific to Aβ peptides but could also 
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1.1 Overview of Alzheimer’s disease (AD)  
Alzheimer’s disease (AD) is the most common form of dementia, affecting around 40 million people 
around the world and global annual estimated for 2018 is the US $1 trillion
1-3
. More than 2.2 million 
South African are living with Alzheimer’s
4
. AD leads to a slow and progressive decline in cognitive 
domains, most commonly involving episodic memory and executive functions which cause 
occupational or social impairment
5
. Despite intense research for decades still, there is no complete 
understanding of the disease etiology. However, the possible cause of AD could be categorized into 
three groups; these are (1) cellular (2) genetic and (3) molecular imbalances
6, 7
. Misfolding and 
aggregation of Amyloid-β (Aβ) peptides
8
, belongs to the molecular imbalance group. 
1.2 Amyloid Cascade Hypothesis  
The amyloid cascade hypothesis proposed by Hardy and Higgins in 1992
9
 and since then it has played 
a crucial role in explaining the etiology and pathogenesis of Alzheimer's disease (AD) and dominated 
research for the past twenty years
10
. It suggests that accumulation of Aβ peptides in the brain is the 
early event in AD, which leads to the formation of senile plaques (SPs) and further neurofibrillary 
tangles (NFTs), causing neuronal cell death, and ultimately dementia. The various experimental 
studies have supported this hypothesis
11
. 
1.2.1 Production of Aβ peptides  
The term amyloid was conied by Rudolph Virchow, in 1854 to represent tissue abnormality that 
exhibited a positive iodine staining reaction
12
. Aβ peptides are cleavage products of the 
transmembrane amyloid precursor protein (APP), which is cleaved by enzyme complexes α, β, and γ-
secretases
13
. (Figure: 1.1) APP cleaved by α-secretase produce N-terminal ectodomain (sAPPα) and 
83-amino acid C-terminal membrane fragment (C83), which is sequentially cleaved by γ-secretase to 
generate non-pathogenic P3 peptide and APP intracellular domain (AICD); this pathway termed as 
“non-amyloidogenic pathway.”  When APP is cleaved by β-secretase instead of α-secretase, it 
produces N-terminal ectodomain (sAPPβ) and 99-amino acid C terminal membrane fragment (C99), 
which is sequentially cleaved by γ-secretase to produce pathogenic Aβ peptide and AICD; this 
pathway termed as “Amyloidogenic pathway”
14, 15
 (Figure: 1.1). Since γ-secretase lacks the ability to 
cleave Aβ peptide accurately, this results in a variable length of Aβ peptides; the most common 







Figure: 1.1 Shows non-amyloidogenic and  Amyloidogenic pathways of APP cleavage.  Aβ region of protein 
has been shown in red and other part has been shown in blue.               
   
1.3 Amino acids sequence of Aβ peptides  
The amino acids sequence of Aβ peptide was discovered in 1984 from extracellular deposits and 
amyloid plaques
17
.  The Aβ1-40 peptide contains 17 hydrophobic, 11 polar and 12 charged residues,  
Aβ1-42 peptide includes 2 additional hydrophobic residues at C-terminal residues,(Figure: 1.2) which 
make Aβ1-42 peptide more toxic and aggregation prone
18.   
    
Figure: 1.2 Shows the amino acids sequence of Aβ1-40 and Aβ1-42 peptides. Negatively charged residues has 
3 
 
been shown in red, positively charged residues has been shown in green, polar residues has been shown in black 
and nonpolar residues has been shown in light blue color.   
 
1.4 Structure of Aβ1-40 and Aβ1-42 Monomers   
The Aβ monomer is an intrinsically disordered peptide (IDP) in the water environment, meaning that 
instead of single dominant folded conformations, Aβ peptide populates a large number of different 
conformation, which makes problematic to crystallize their structures
19, 20
. The knowledge of Aβ 
monomers structures has been majorly driven from NMR and MD simulations. In the membrane-
mimicking environment, Aβ1-40 and Aβ1-42 monomers predominantly remain  an α-helical 
conformation. The Aβ1-40 monomer region, Asp1-His14 remains unstructured, and the region 
between residues, Gln15 to Val36 adopts a α-helical conformation with a turn around Gly25-Asn27
21
 
(Figure: 1.3B). Aβ1-42 monomer contains two α-helix regions: i) helixI (Ser8-Val24) and helixII 
(Lys28-Val38) and a turn region around (Gly25-Lys28)
22, 23
 (Figure: 1.3C).  Aβ1-40 monomer 
structure in complete aqueous environment reveals that the region between His13-Asp23 forms a 310-
helix and the N- and C-terminal remains unstructured
24
 (Figure: 1.3A).  The Aβ1-42 monomer 
structure in 70% aqueous environment reveales that the region between Try10-Asp23 remained in α-
helix conformation and the region between Leu34-Gly38 contains a certain degree of helical structure 
and the Gly25-Lys28 region forms a turn
25
 (Figure: 1.3D). All the structure mentioned above of Aβ 
monomers has been resolved in different in-vivo environments by representing a range of 100% water 
to micelle-like membrane environment. In Table: 1.1 we have summarized structures and their 
environment. 
PDB id  In vivo environment  
2LFM
24
 (Aβ1-40 monomer) 100% water 
1BA4
21
 (Aβ1-40 monomer) Water-micelle like environment 
1IYT 
22
 (Aβ1-42 monomer) 20% water 
1Z0Q
25
 (Aβ1-42 monomer) 70% water 
Table: 1.1 Aβ1-40/42 in different in vivo environments. 
These structures could be further categorized by their α-helix content; as the water content increases 
there is a loss of α-helix content observed in these structures. The Aβ peptide present in the micelle-
like environment has the highest α-helix content, and the one in 100% water environment has the 






Figure: 1..3 A) Shows Aβ40 monomer structure (PDB ID: 2LFM). B) Shows Aβ42 monomer structure  
(PDB ID: 1IYT). B) Shows Aβ40 monomer structure (PDB ID: 1BA4). D) Shows Aβ42 monomer 
structure (PDB ID: 1Z0Q). The monomers  have been shown in cartoon represen representation, and α-
helix region has shown in red color, and unstructured region has been shown in blue color and turns 
region has been shown in green. 
MD simulations of Aβ monomers in aqueous and membrane environment have provided crucial 
information about these peptides. Luttmann et. al.
26
 performed MD simulation  of full-length Aβ 
monomers in aqueous environment their data revealed that Ala21-Gly33 forms a turn region and 
residue between Asp1-Tyr10 are highly flexible. Agrawal et. al.
27
 performed MD simulation of Aβ1-
40 and Aβ1-42 monomers in an explicit water environment and their data  revealed that a gain of 
water molecules around Lys28 and a loss of water molecules around Val24 play a key role in turn 
formation. Valerio
28
 et al. performed MD simulation study of Aβ1-40  and their results showed that 
hydrophobicity, flexibility, and mobility of N-terminal region is important for obtaining misfolded 
structure. Miyashita
29
 et al. performed the replica-exchange simulation of Aβ1-40 and Aβ1-42 in 
membrane environment and their results showed that the C-terminal region of both peptides favors 
membrane environment and N-terminal region favors aqueous region and forms a coil.  
1.5  Different shapes of Aβ fibrils 
Aβ fibrils are non-crystalline and insoluble in water, which makes them incompatible with solution 
NMR and x-ray crystallography
30
. However, techniques like x-ray diffraction
31
 solid-state NMR (SS-
NMR)
32
, transmission electron microscopy (TEM)
33





, and MD simulation
36
 have provided valuable information about Aβ fibrils. 
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X-ray diffraction studies helped to establish that Aβ fibril forms “cross-β-sheet” structures
37-39
, in 
which Aβ peptides assemble into β-sheets with β-strands oriented perpendicular to the long axis of the 
fibril and stabilized by H-bonds. β-sheet structures of Aβ fibrils were further confirmed by binding of 
β-sheet specific dyes such as thioflavin-T and Congo red
40, 41
. SS-NMR studies have revealed that Aβ 
fibrils contain two β-sheets, and these β-sheets are connected by a turn region, which gives Aβ fibrils 
a dual-sheet motif or “U-shaped” topology (Figure: 1.4A). The region between two β-sheet contains a 
hydrophobic core, which is completely devoid of water molecules
42, 43
. There are several factors, 
which play an important role in the stability of these fibrils and these are the following:  i) hydrogen 
bonding between the backbone amide groups of two nearby chains. ii) VdW interactions between top 
and bottom β-sheets in the hydrophobic core region. iii) enhancement in the entropy of water 
molecules that are expelled from the interior of two β-sheets, and iv) salt-bridge between Asp23-
Lys28
44, 45
. Recent studies have revealed that “S-shaped” structure of Aβ1-42 fibrils, which contains 
three β-sheets, β1 (12–18), β2 (24–33), and β3 (36–40) in which Lys28 formed a salt bridge with the 
Ala42 carboxyl terminus
46-48
 (Figure: 1.4B). . Rodriguez
49
 et al. performed MD simulations of “S-
shaped” Aβ1-42 fibrils in water with 150mM NaCl and their data showed  that monomer is not stable 
in its “S-shaped” structure. However, a dimer of Aβ1-42 peptides showed stability and retained its S-
shaped conformation. 
Cryo-EM has provided a new finding in this field; a recently resolved structure using cryo-
EM revealed that Aβ fibril structures obtained an “L-S” shape (Figure: 1.4C).  In the "L-S" shaped 
structure the N-terminus is "L-shaped," and the C-terminus is "S-shaped." There are three 
hydrophobic clusters present in the structure i) Ala2, Val36, Phe4, and Leu34, ii) Leu17, Ile31, and 





 et al. using high-speed AFM revealed the fibril formation and elongation of Aβ1–42 and 
their data showed two different growth modes of Aβ1-42; the first one produces straight fibrils and 
the second one produces spiral fibrils. TEM studies have revealed that as Aβ fibrils are straight, 
unbranched filaments that are approximate,10 nm in size, which often exceeds up to 1 μm
52
.  MD 
simulation studies have provided important insights about the structural stability of Aβ 
protofibrils/fibrils, e.g., Masman et al.
53
 performed MD simulation of Aβ1-42 fibrils; their data 
suggested that the hydrophobic core region is crucial in stabilizing the Aβ aggregates. Lemkul et. al.
54
 
performed MD simulations of Aβ protofibrils and their results revealed that a finite level of hydration 
around the Asp23-Lys28 salt bridge is crucial for protofibril stability. Their data further showed that 
interaction between Ile32 and the aliphatic portion of the Lys28 side chain regulates the level of 
hydration in the core of the protofibril. 
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Figure 1.4 A) Shows Aβ17-42 fibrils “U-shaped” structure PDB id: 2BEG
55
. B) Shows “S-shaped” structure of 
Aβ1-42 fibrils PDB id: 2MXU
46
. C) Shows “L-S” Shaped Aβ1-42 fibrils PDB id: 5OQV
50
.  Structure of Aβ 
fibrils has shown in new cartoon representation and salt--bridge formed by them in CPK representation. 
1.5.1 Arrangement of Aβ fibrils in two-symmetry and three-fold symmetry  
In the two-fold symmetry, Aβ fibril structures contain two symmetric strands that form separate β-
sheets in a double-layered, cross-β motif. The two protofilaments aggregate in the fibril growth 
direction and have a helical symmetry along the axis (Figure: 1.5A-E). In the three-fold symmetry, Aβ 
fibrils contain three β-strands that form separate β-sheets in a triangular cross-β motif arrangement 
and same as two-fold symmetry structure. These three protofibrils can aggregate in the fibril growth 
direction and also have a helical symmetry along the axis
56
 (Figure: 1.5E). In two-fold symmetry 
packing of “U-shaped”  (Figure: 1.5A), Aβ fibrils Met35 interacts along and across the fibril axis and 
stabilize the two-fold symmetry structure. Wu
57
 et al. performed MD simulations of “U-shaped” Aβ9-
40 fibrils in two-fold symmetry in six different possibilities, their results revealed that in all the 
possibilities hydrophobic residues stabilized the interface between two units. Colvin
47
 et al. 
determined Aβ1-42 fibrils structure in two-fold symmetry. In this structure, each β-strand in “S-
shaped” (Figure: 1.5B) and arranged in such a manner that generates two hydrophobic cores, and 
interchain contacts of two units formed between residues Met35 and either Leu17 or Gln15. These 
factors mentioned above help to stabilize "S-shaped" Aβ fibrils in the two-fold symmetry (Figure: 
1.5B). Wang
58
 et al. performed MD simulations of “S-shaped” structure of Aβ1-42 fibrils in the 
two-fold symmetry in two different arrangement, PSA (packing between β1-β1) and PSB (packing 
between β3-β3). In PSA, packing Lys16 of one unit formed a salt-bridge with Glu22/Asp23 of 
another unit and stabilized the two-fold symmetry structure. In PSB packing, the Val40 side chain 
formed contact with Gly38 of another unit to stabilize the structure in two-fold symmetry. “LS-
shaped structure of Aβ1-42 fibrils in two-fold symmetry revealed that β-strands of different units 
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 et al. study showed  Aβ1-42 fibril  in “tilde-shaped” conformation arranged 
in two-fold symmetry, in which the C-terminal region of the peptide is surrounded by the N-
terminal region. This arrangment leads to the formation of a hydrophoic core region between C 
and N-terminal (Figure: 1.5D). Wälti
48
 et al. resolved the atomic-resolution structure of  Aβ1-42 
fibril arragned in two-fold symmetry, in which residues 15-42 form a double-horseshoe–like 
cross–β-sheet with maximally buried hydrophobic side chains. Residues 1–14 are partially ordered 
and in a β-strand conformation. Miller
59
 et al. performed MD simulations of “U-shaped” Aβ1-40 
fibrils in three-fold symmetry and their results showed that Met35 formed interactions along the 
fibril axis and Ile31-Val39 of different cross-β units formed interactions. Their data further showed 
Aβ1 –40 triangular structure has a large cavity along the fibril axis and the N—terminal help to 
stabilize the structure in three-fold symmetry by interacting C-terminal domains of other units.  
Dong
60
 et al. performed MD simulation of “U-shaped” Aβ40 fibrils in two-fold and three-fold 
symmetries and their results suggested that packing of “U-shaped” Aβ40 fibrils in the two-fold 
symmetry are more stable in comparison to the packing of “U-shaped” Aβ40 fibrils in the three-
fold symmetry.  
             
Figure: 1.2 A) Shows “U-shaped”  Aβ9-40 fibrils (PDB ID: 2LMN
42
) in two-fold symmetry.  B) Shows “S-
shaped” Aβ1-42 fibrils (PDB ID: 5KK3
47
) in two-fold symmetry.  C) Shows “LS-shaped” (PDB ID: 5OQV
50
) 
Aβ1-42 fibrils in two-fold symmetry. D) Shows “Tilde-shaped” (PD ID: 5AEF
34
) Aβ1-42  fibril in two-fold 
symmetry. E) Shows “Horseshoe-shaped” Aβ1-42 fibril in two-fold symmetry (PDB ID: 2NAO
48
). F) Shows 
“U-shaped” Aβ1-40 fibrils (PDB ID: 2M4J
61
) in the three-fold symmetry. All the fibrils have shown in new-
cartoon representation, and contact residues have been shown CPK. Hydrophobic residues have been shown in 
white, polar residues have been shown in green, negatively charged residues have been shown in red, and 
positively charged residues have been shown in blue. 
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1.5.2 Polymorphism in Aβ fibrils and its implications 
Now its very evident that the structure of Aβ fibril does not depend on the amino acids sequence
62
, as 
we have mentioned in the previous section that Aβ peptides can arrange in the different shapes and 
symmetries. The polymorphism in Aβ fibril structures suggests that multiple interaction sites present 
within each Aβ molecule, give rise to differences in fiber morphologies and physicochemical 




1.5.3 Elongation of Aβ fibrils 
Elongation of Aβ fibrils is a very complex process and studies have suggested that it takes place by 
the inclusion of structured/unstructured monomers at the fibril tips
65
. This process is termed as "dock 
and lock" mechanism. In the first step (docking) of this process, a monomer “docks” to the Aβ fibrils 
surface and in the second step (locking) the monomer undergoes conformation rearrangements to 
form the native contacts present in Aβ fibrils
66
.  A MD simulation study by Schwierz
67
 et al. has 
revealed that solvent entropy is the major driving force in the elongation process. Their data further 
showed that  the “docking” stage (Figure: 1.6 A, B)  is fast as interactions are mediated by transient 
non-native hydrogen bonds and the “locking” stage (Figure: 1.6 C) is very slow due to the formation 
of long-lived non-native hydrogen bonds. Bacci
68
 et al. performed MD simulation of Aβ42 pentamer 
to study the elonagtion process and their data revealed that in the both “docking” and “locking” steps, 




Figure:1.6 A) Shows misfolded Aβ monomer and Aβ fibrils B) “Docking” stage of monomer association with 
Aβ fibrils C) Shows “Locking” stage of Aβ monomer association with Aβ fibrils. 
 
1.6 Aβ aggregates/Fibrils interaction with Membranes  
Studies have suggested that Aβ aggregate/fibrils form a nonspecific association with cell membranes 




 et al. experimental 
study suggested that aggregated Aβ decreases the fluidity of membranes. Lindberg
71
 et al. work 
revealed that charged lipid membranes which represent the outer cell membranes can significantly 
increase autocatalytic steps in the self-assembly of Aβ1 –42 into fibrils. Xiang
72
 et al. performed MD 
simulation of Aβ11-42 aggregate/fibrils with membranes and their data revealed that Aβ peptides larger than 
two peptides could lead to the lipid deformation and water channel formation. Scala
73
 et  al. study revealed 
the molecular mechanism of pore formation in the membrane by the Aβ oligomer aggregates; they showed 
cholesterol and ganglioside interact with amyloid proteins, which leads to the creation of pores in the 
membranes. Martins
74




          
Figure: 1. 7 Shows different stages of Aβ peptides from monomers to fibrils (at any stage, they can  interact  with the 
biological membrane). 
1.7 Inhibitors of Aβ Proteins Toxicity  
Misfolding and aggregation of Aβ monomers is the first step in a multi-step pathway to form neurotoxic 
soluble oligomers and mature Aβ fibrils. Toxicity of an independent Aβ monomers is still debatable as some 
studies suggest that they are toxic
75
 and other labeled them as nontoxic
76
. However, there is a consensus in 
the scientific community regarding the toxicity of Aβ oligomers
77, 78
 . Aβ fibrils are also neurotoxic as they 
can interact with the cell membranes
74, 79
. Inhibition of misfolding and aggregation of Aβ peptides and 
remodeling the Aβ fibril morphology could significantly reduce its cytotoxicity
80,61
.   
In past decades, several Aβ peptide inhibitors have been discovered and many of them failed in the 
preclinical stage; some of them failed in advanced clinical stage (Phase III). Below we discuss the molecule 
and antibodies which went into clinical phases II and III.  To best of our knowledge these are the antibodies, 
which  has enterted in to clinical phase III.  
 1.7.1 Tramiprosate (Alzhemed®) 
Homotaurine is an amino sulfonate compound (Figure: 1.8A), which is extracted from marine red 
algae
81
.  These compounds were chemically synthesized and introduced into clinical use as 
tramiprosate by Neurochem, Inc
82
.  In vitro studies have shown that Alzhemed (Figure: 8A) 
preferentially binds to soluble Aβ peptides, inhibits their aggregation and fibrillogenesis and reduces 
Aβ neurotoxicity. Martineau
83
 et al. suggested that Homotaurine binds with Aβ peptides using its 
sulfonate head group. It has also been shown that Tramiprosate could reduce ~30% Aβ plaque level in 
the brain
84
.  The clinical phase III study of Tramiprosate was carried out in the United States in 1052 
patients with AD to test the efficacy, tolerance, and safety of the Tramiprosate, but unfortunately, 







Solanezumab is an anti-Aβ peptide monoclonal antibody developed by Eli Lilly. Crespi
86
 et al. 
resolved the crystal structure of Solanezumab complex with Aβ peptide and their results showed that 
Solanezumab recognized the mid-region residues, 16-26, of Aβ peptide. Their results further revealed 
that Aβ16-26 forms extensive contacts and hydrogen bonds to the Solanezumab and Aβ binds to the 
Solanezumab in an unstructured conformation (Figure: 1.8B). The rationale to use Solanezumab as an 
anti-Aβ peptide was that it could remove small, toxic, soluble Aβ peptides, which may lead to the 
reduction in synaptic toxicity. The clinical phase I and II studies showed that Solanezumab was 
tolerated in both healthy and AD patients without any side effects
87, 88
. However, Solanezumab failed 
to demonstrate efficacy in the clinical phase III
89
.  
1.7. 3 Bapineuzumab (humanized 3D6) 
Bapineuzumab is an anti-Aβ monoclonal antibody developed by Pfizer and Johnson & Johnson. 
The rationale to use Bapineuzumab as an anti-Aβ antibody was that it could clear excess Aβ 
peptides. Feinberg
90
 et al. resolved the crystal structure of  Bapineuzumab complex with Aβ 
peptide and their results showed that Bapineuzumab antibody specifically recognized Aβ residue 
1-5 with a strong preference for an exposed Asp residue at the N-terminus. Their results further 
revealed that Aβ1-5 bound in 310-helix conformation with Bapineuzumab. In another study Miles
91
 
et al. also resolved the crystal structure of Bapineuzumab complex with Aβ. Their results revealed 
that Bapineuzumab binds to the N-terminal end of the Aβ (residues 1-6) in a helical conformation 
(Figure: 1.8C). The clinical phase I and II studies showed that Bapineuzumab was well-tolerated in 
patients with mild to moderate AD. However, Bapineuzumab also failed in phase III clinical trial, 






Figure: 1.8 A) Shows the structure of Homotaurine (PubChem CID: 1646). B) Shows Aβ16-26 bound with 
Solanezumab (PDB id:4XXD
86
). C) Shows Aβ1-6 bound with Bapineuzumab (PDB id: 4HIX
91
). 
The failures of above-mentioned candidate drug molecule/antibodies at clinical stages (II and III)  has 
driven the research to explore the new strategies for developing drugs for AD.  Tian
94
 et al. proposed 
a new approach to attenuate the aggregation of Aβ peptide through a non-covalent modification at its 
surface and  reasoned that crown ethers could be exploited to “neutralize” positive charges of the 
amino groups of Aβ peptide through the formation of hydrogen bonds. 
1.8 Crown ethers 
Crown ethers are small cyclic polyethers, first synthesized by 1987 Nobel Prize winner in chemistry 
Charles J. Pedersen
95, 96
.  Crown ether molecules have been widely applied in biological chemistry, 
probe chemistry,
97, 98




 et al.  used crown ethers as permeability 
enhancers for ocular drug delivery. Lee
102
 et al.  performed an experimental and MD simulations 
study  to reveal that crown ethers could modify protein surface behavior dramatically by stabilizing 
either intra- or intermolecular interactions. Banik
103
 et al. used crown ethers for inhibition of fibrillar 
assemblies of l-Phenylalanine. Angelinia
104
 et al. complexed crown ethers with lipid, and applied as 
potential DNA vectors. There is no crown ether based molecule that has entered into clinical trials for 
the Alzheimer’s disease until now; however, a 12-crown-4 fused quinazoline drug name Icotinib is in 
the market as an inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK)
105.
 Even 
though the 12-crown-4 may not be a viable drug, the molecule is small, cheap (sigma sells it in 80 
euro/5grams purity 98%) and easy to manage,which makes 12-crown-4 suitable for the lab and  useful 
for simulations. Understanding the 12-crown-4 binding mechanism to Aβ proteins will generate the 
knowledge, which could be utilized to design new more potential drug molecules. 
  
 
1.9 Aim and objectives  
The aim of this thesis is to carry out MD simulations to reveal the molecular mechanism of 12-crown-
4 binding to Aβ40, Aβ42  monomers, Aβ40 fibril trimer and  Aβ9-40 fibrils hexamer binding to 
cholesterol-rich DPPC bilayer.   
The following objectives of this work were: 
1)  Role of  water in turn formation or early stage misfolding of Aβ1-40 and Aβ1-42 monomers.  
2) Identify  the  region of 12-crown-4 binding and its impact on Aβ1-40 and Aβ1-42 monomers 
conformations. 
3) Effect of 12-crown-4 binding on conformation entropy of Aβ monomer.  
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4) Decipher the binding modes of 12-crown-4 on Aβ40 fibril trimer and effects of binding on its 
conformations.  
5)  Reveal the mechanism of Aβ9-40 hexamer fibrils binding with cholesterol-rich DPPC bilayer. 
 
 
1.10 Overview of thesis  
This thesis will take the following form 
Chapter-2: will discuss the basics of molecular dynamics (MD) simulations. 
Chapter-3: (Published work- this chapter is presented in the required format of the journal and the 
final accepted version) 
This chapter deals with a research paper entitled “Binding of 12-Crown‑4 with Alzheimer’s Aβ40 and 
Aβ42 Monomers and Its Effect on Their Conformation: Insight from Molecular 
Dynamics Simulations”; which was published in ACS Molecular Pharmaceutics
27
. This chapter 
describes the role of water in the turn formation in Aβ40 and Aβ42 monomers and binding of 12-
crown-4 with these monomers using all-atom MD simulations. 
Chapter-4: (Published work- this chapter is presented in the required format of the journal and the 
final accepted version) 
This chapter deals with a research paper entitled “12-Crown-4 Ether Disrupts the Patient Brain-
Derived Amyloid-β-Fibril Trimer: Insight from All-Atom Molecular Dynamics Simulations”; which 
was published in ACS chemical neuroscience
45
.  This chapter describes binding modes of 12-crown-4, 
on patient brained derived Aβ40 fibril using all-atom MD simulations. 
Chapter-5: (Submitted work – this chapter is presented in the required format of the journal and is the 
final version of the submitted manuscript) 
This chapter deals with a research work entitled “Binding of Alzheimer’s Amyloid βeta9-40 Fibrils with 
Cholesterol-rich DPPC Bilayer: Insight from Coarse Grained Molecular Dynamics Simulations”; 
which has been submitted to ACS Journal of Physical Chemistry B. This chapter describes the 
binding of Aβ9-40 fibril hexamer binding with cholesterol-rich DPPC bilayer using coarse-grained MD 
simulations.  
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2. Molecular Dynamics Simulations 
 “If we were to name the most powerful assumption of all, which leads one on and on in an attempt to 
understand life, it is that all things are made of atoms, and that everything that living things do can be 
understood in terms of the jigglings and wigglings of atoms”. 
   -----Richard Feynman, recipient of the 1965 Nobel Prize in Physics 
2.1 Introduction 
The MD simulations were originated within the theoretical physics community during the 1950’s; the 
earliest reported simulation was performed by Alder and Wainwright in 1957
1
.  The first protein 
simulation was performed in 1976
2, 3





 and material sciences
6
. MD simulations have been very 




, protein-ligand binding and 
impact of the ligand on protein dynamics
10
. MD techniques are also widely used in the refinement of 






. There are various 
dynamics processes that take place in proteins, which could range from femtoseconds to hours
14, 15
 
and depending on the process needed to be studied, different level of approximation can employed. 
Figure: 2.1 shows time dependent events in protein dynamics.  
  
      Figure: 2.1 Shows the time-dependent in protein dynamics. 
2.2 Theory  
MD simulation is a computational technique used to understand the time-dependent behaviour of 
biomolecules, their kinetics and thermodynamics. MD simulation is based on Newton’s second law of 
motion; where the forces are obtained as gradients of the potential energy.  Integration of the equation 
of motion produces a trajectory containing positions, velocity and accelerations of atoms along the 
time. Enhancement of computational hardware and algorithms has helped researchers to simulate 





Newton’s equation of motion is given by 
                                                         𝐹𝑖 = 𝑚𝑖 𝑎𝑖      (2.1) 
Where  Fi is the force exerted on particle i, mi is the mass of particle i and ai is the acceleration of 
particle i.  






                               (2.2) 
                         
𝑑𝑟𝑖
𝑑𝑡2
= 𝑎𝑖      (2.3) 






      (2.4) 
Force is the derivative of potential with respect to position that can be calculated analytically. We then 
need to integrate the force to obtain the velocities and the positions in the next time step. Various 
algorithms are available for integrating the equations of motion. Many of these are finite difference 
methods in which the integration is partitioned into small steps, each separated in time by a specific 




2.2.1 Verlet algorithm 
 Verlet integration is a numerical method used to integrate Newton's equations of motion. It is 
frequently used to calculate trajectories of particles in molecular dynamics simulation.   
                                 𝑟(𝑡 + 𝛿𝑡) = 𝑟(𝑡) + 𝑣(𝑡)𝛿𝑡 +




                                         (2.5) 
Where, r is positions of atoms, t is time, v is velocities of atoms and a is accelerations of atoms. 
                                 𝑟(𝑡 − 𝛿𝑡) = 𝑟(𝑡) − 𝑣(𝑡)𝛿𝑡 +
1   
2
a(t)𝛿t2                                         (2.6)    
The addition of the above two equations, produces:  
                               𝑟(𝑡 + 𝛿𝑡) = 2𝑟(𝑡) − 𝑟(𝑡 − 𝛿𝑡)𝛿𝑡 +a(t)δt2                                     (2.7) 
2.2.2 Velocity Verlet algorithm   
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This algorithm generates positions, velocities and accelerations at time t. There is no compromise on 
precision. 
          𝑟(𝑡 + 𝛿𝑡) = 𝑟(𝑡) + 𝑣(𝑡)𝛿𝑡 +




                                (2.8) 
 
                               𝑣(𝑡 + 𝛿𝑡) = 𝑣(𝑡) +
1
2
 [𝑎(𝑡) + 𝑎(𝑡 + 𝛿𝑡)] 𝛿𝑡                      (2.9)   
 
2.2.3 Leapfrog algorithm 
The leapfrog algorithm uses the positions at time t and the velocities at time t − (Δt/2) for the update 
of both positions and velocities. 
                            𝑟(𝑡 + 𝛥𝑡) = 𝑟(𝑡) + 𝑣 (𝑡 +2
1 𝛥𝑡)𝛥𝑡                                                      (2.10) 
                           𝑣 (𝑡 +2
1 𝛥𝑡) =  𝑣 (𝑡 −2
1 𝛥𝑡) +a(t)Δt                                                       (2.11) 
Velocities at time t can be approximated by the following expression: 






𝛥𝑡)  + 𝑣 (𝑡 +
1
2
𝛥𝑡)]                                            (2.12)         
2.3 Force fields 
The term “force field” refers to the mathematical expression and associated parameters that describe 
the energy of the system as a function of its atomic coordinates
16, 17 
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]                      
Bonded forces emerge through bonds and angles are modeled using simple virtual springs, and 
dihedral angles are modeled using a sinusoidal function that approximates the energy differences 
between eclipsed and staggered conformations. Non-bonded forces emerge due to van der Waals 
interactions, modeled using the Lennard-Jones 6-12 potential and charged (electrostatic) interactions, 
modeled using Coulomb's law
18
.                             
      Non-bonded  
 Bonded  





2.4 Type of force field 
There are three types of force fields: 










2.4.3) Coarse grained:  an abstract representation of molecules by grouping several atoms into 
"super-atoms.”e.g. ,MARTINI
23 . 
2.5 Ensembles: An ensemble is a collection of all possible systems that have differing microscopic 
states but belong to a single macroscopic or thermodynamic state. Various different formal ensembles 
with differing characteristics exist. The most widely simulated are as follows: 
2.5.1 The canonical ensemble (NVT): This is the collection of all systems whose 
thermodynamic state is characterized by a fixed number of atoms, N, fixed volume, V, and fixed 
temperature, T.  
2.5.2 The isobaric-isothermal ensemble (NPT): An ensemble with a fixed number of atoms, N, 
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3.1 Abstract 
Alzheimer’s disease is the most common form of dementia and is considered to be caused by the 
conformational change of Aβ monomers, from their native monomeric states, to form Aβ 
oligomers/aggregates in the brain. Turn formation in Aβ monomer has been suggested to be the 
nucleation step for Aβ misfolding.  In the present work, we have performed a series of    all-atom 
molecular dynamics simulations, a total time of 11.4 μs, to elucidate factor that contributes for early 
stage misfolding of Aβ40 and Aβ42 monomers and reveals the binding modes of 12-crown-4 on Aβ40 
and Aβ42 monomer and effect of its binding on structural stability. Our simulation data revealed that 
the region around Val24-Lys28 is most prevalent for turn formation and a gain of water molecules 
around Lys28 sidechains occurs at the same time as a significant gain in conformational entropy of 
the sidechain.  The initiation steps lead a greater number of water molecules available and 
enhancement of the conformational entropy of the backbone atoms; this leads to greater probability of 
breaking Lys28 backbone intra-peptide H-bonds, and consequently turns formation.   
Simulations of Aβ40 and Aβ42 monomers with 12-crown-4 showed that the molecule is highly 
specific towards positively charged Lys16, Lys28 residues, and N-terminal Asp1.  Lys16 and Asp1 
have been previously reported to make Aβ peptide toxic. Our secondary structure analysis revealed 
that in the absence of 12-crown-4 there was a β-sheet formed in the Aβ40 peptide. In case of Aβ42 
monomer, in the absence of 12-crown-4, we observed that the second helix region converted into a 
coil and turn; however, in the presence of 12-crown-4 it remained stable.  
Observed pharmacophore features of, 12-crown-4  will not only help in designing new candidate drug 
molecules, which are specific to Aβ peptides but could also be used to design new imaging probe 
molecules, which could be used for labeling Aβ peptide 
 





Alzheimer’s disease (AD) is the most prevalent form of neurodegenerative disease, affecting around 
40 million people worldwide
1,2
.  Since  its first description by a psychiatrist and neuropathologist 
Alois Alzheimer, in 1907, there is still no known cure for this illness, majorly due to lack of complete 






The most widely accepted amyloid cascade hypothesis 
suggests that Amyloid-β (Aβ) peptide misfolding and  aggregation is the principal culprit for AD
6
.  
The Aβ peptide is produced from the amyloid precursor protein (APP) by the proteolytic activities of 
β and γ-secretase. Since γ-secretase is unable to cleave  Aβ peptide precisely, this results in a variable 
length of Aβ peptides; the most common isoforms being Aβ40 and Aβ42
7
.   
      NMR and MD simulations studies have suggested that Aβ monomer misfolding is nucleated by 
the formation of a turn around Val24-Lys28 and these studies  have further highlighted  various 
important  factors that contribute to the turn formation and stabilization of misfolded Aβ monomer; 
these factors are 1) The  intrinsic, conformational properties of the Val-Gly-Ser-Asn and Gly-Ser-
Asn-Lys sequences to form the turn
8
.  2)  The long range electrostatic interactions between Lys28 and 
Glu22 or Asp23
9, 10
. 3) Hydrophobic interactions between Val24 and Lys28 sidechains 
8, 9, 11, 12
  4)  
Hydrogen bond formation between the negatively charged Asp23 side chain with the backbone atoms 
of the turn region residues, Gly25, Ser26, Asn27, and Lys28
9
.   
Various MD simulation studies of Aβ peptide, in an explicit water environment, have suggested the 
importance of the displacement of water molecules around the hydrophobic and hydrophilic region in 
Aβ misfolding and aggregation. Khatua et. al.
13
 revealed that water molecules around the hydrophobic 
region are relatively weakly bound and expected to be easily displaced during the hydrophobic 
collapse.  In another study Melquiond et.al.
14
  it was revealed that water molecule expulsion took 
place in the hydrophilic region between  residue 22 and residue 28 to form the aggregates/fibrils.  
Tarus et. al.
12
 revealed that an early event in the oligomerization process is the expulsion of water 
molecules that facilitate the turn formation around residues 24-27.  It has been suggested that intra-
peptide H-Bonds play a key role in stabilizing the folded forms of proteins and H-bond cooperativity 
plays an important role in stabilization of  a α-helix
15,16
.  It is widely appreciated that hydrated water 
molecules, around proteins, form H-bond networks and play a crucial role in dynamics and 
stabilization of protein structure
17
.  The presence of hydrated water molecules around the backbone 
causes lengthening of intra-peptide H-bonds within the backbone, thus loosening the structure
18
.  
To investigate the inhibition of the Aβ peptide misfolding and aggregation by a candidate 
drug molecule, several studies have been performed. Hernández-Rodríguez  et. al.
19
 performed an in-
silico and in-vitro study of galanthamine with Aβ42  their results revealed that galanthamine binds 






by a mass spectrometry and solution-state NMR study, revealed that a “molecular tweezer”, CLR01, 
specifically binds with Lys16 and Lys28 at the monomer stage which resulted in the formation of 
nontoxic structures of Aβ. Sinha et. al.
21
 revealed, by a mutational study, that  substitution of  Lys16 
for Ala significantly reduced Aβ toxicity. All these studies have highlighted the importance of Lys16 
and Lys28 in the conversion of Aβ monomers to Aβ aggregates/fibrils and their toxicity.   
The Conformational entropy of proteins is a proxy measure of  its conformational dynamics, 
which is directly related to a number of conformation obtained by it
22,23
.  It has been suggested that 
loss of backbone and sidechain conformational entropy plays an important role in protein stability
23, 24
 
. Conformational entropy significantly contributes to binding affinity and specific association between 
a protein and its ligand
25
 and it has been revealed that binding of  a ligand with  a protein leads to the 
loss of conformation entropy of  both ligand and protein binding residue
26,27
.  A candidate molecule 
that can bind strongly to key residues should be able to counteract conformational entropy losses upon 
binding, and, therefore, could play an important role in the stability of the protein. 
Crown ethers are small cyclic polyethers, first discovered by Nobel Prize winner Charles 
Pedersen more than 50 years ago.  Due to their strong binding affinities to various metal ions and 
primary amines, members of the crown ether family have been widely applied in biological chemistry 
and probe chemistry 
28, 29,30,31
.  Oukhatar  et. al.
32
 used crown ethers to design molecular magnetic 
resonance imaging  (MRI) sensing probe for neurotransmitters. Gawley et. al.
33
 used crown ethers to 
design visible fluorescence chemosensors for Saxitoxin (a potent neurotoxin). In another study, Işık et 
.al.
34
 used crown ethers to design an intracellular fluorescent probe for Glutathione (GSH), that 
worked satisfactorily inside the human breast adenocarcinoma cells, and highlighted  GSH 
distribution in the cytosol. All these aforementioned studies revealed that crown ethers can be used for 
imaging probes. 
 A recent study by Tian et. al.
35
 showed the testing of  12-crown-4 and 12-crown-4 conjugated 
with Pittsburgh compound B (PiB) a positron emission tomography (PET) tracer and targeting agent 
widely used for Aβ imaging.  It was shown that 12-crown-4 ether and 12-crown-4 conjugated 
Pittsburgh compound B (PiB-C) inhibits the Aβ40 aggregation. It was revealed that the aggregation of 
Aβ40 was significantly reduced by 12-crown-4 and PiB-C.  Furthermore, a dot blot experiment 
showed that in the presence of 12-crown-4 and PiB-C, a significantly lower number of 
fibrillar/prefibrillar structures were formed than in its absence or with PiB (PiB without conjugation). 
To investigate whether 12-crown-4 can reduce the Aβ42 toxicity, the authors treated SH-SY5Y 
neuronal cells with Aβ42 in the absence and presence of 12-crown-4, PiB and PiB-C; their data 
revealed that 12-crown-4 and PiBC could significantly reduce the toxicity of Aβ42.  Two-photon 
microscopic imaging data revealed that PiB-C could readily penetrate the blood -brain barrier (BBB) 
and efficiently label Aβ.  Overall the data of the aforementioned study suggested that 12-crown-4 and 
PiB-C could efficiently inhibit the aggregation of Aβ monomers into protofibrils/fibrils. The authors 
32 
 
hypothesized that hydrogen bonds between crown ethers and positively charged amino acids of Aβ 
such as Arg5, Lys16, Lys28, His13 and His14 inhibited/modified its aggregation. An experimental 
and computational study by Lee et. al. 
36
  revealed that crown ethers can modify protein surface 
behaviour dramatically by forming intra- or intermolecular interactions and they proposed that crown 
ethers can be used to modulate protein oligomerization/aggregation. In our previous study, we 
performed MD simulation of 12-crown-4 with Aβ40 fibrils trimer
37
 and revealed three binding modes 
of 12-crown-4 on Aβ40 fibrils trimer.  In the first binding mode, 12-crown-4 ether entered into the 
hydrophobic core and opened the “U-shaped” topology of Aβ40 fibril trimer, which is important for 
its cytotoxicity
38
.  In the second binding mode, 12-crown-4 interacted with Lys28 breaking the salt-
bridge formed between Asp23-Lys28, which plays an important role in aggregate/fibril stability
39
.  
Lastly, 12-crown-4 specifically interacted with Lys16, which is important for toxicity
20
.  
   In the present study, we aim to find a molecular basis for the early steps misfolding of Aβ 
peptides and effect of 12-crown-4 ether on Aβ40 and Aβ42 monomers misfolding, To fulfill this aim 
we have performed 29 all-atom molecular dynamics (MD) simulations, with a total simulation time of 
11.4μs, in the presence and absence of 12-crown-4; these methods allow us to study the Aβ40 and 
Aβ42 monomers conformation dynamics and monitor the interaction between the 12-crown-4 and the 
Aβ40 and Aβ42 monomers. The MD study will allow us to answer the following questions: 1) How 
does turn-formation take place in Aβ monomers? 2) What is the role of water solvation around turn-
region residues in turn-formation? 3) Which region does 12-crown-4 bind to?  4)  What is the impact 
of 12-crown-4 binding on Aβ40 and Aβ42 monomers? 5) How does 12-crown-4 binding with Aβ40 
residues affect its conformational entropy and what are the implications of such entropy changes?  
 
3.3 Methods  
3.3.1 Structure and Force field for Aβ40 Monomer 
In the present molecular dynamics study, NMR derived Aβ40 monomer (PDB id: 1BA4) and Aβ42 
monomer ( PDB id :1IYT) structures have been used  (Figure: 3.1A, B).  The Aβ40 monomer 
structure contains 1-14 unstructured region;  the rest of the peptide adopts α-helical conformation 
40
. 
The Aβ42 monomer structure contains two helical regions first one from residues 8–25 and the second 
one from 28–38, both regions connected by a regular a β-turn
41
.  In this study we have used 
Charmm36 force field
42
 for Aβ40 and Aβ42 monomer; a recent study  Siwy et.al.
43
  performed a 
comparative  MD simulation study of  Aβ10-40   using four different protein force fields and two water 
models (standard TIP3P and modified TIP3P). Their data revealed that J-coupling and residual dipolar 
coupling constants of the Charmm36 force field, with standard TIP3P water model, was in the close 
agreement with experimental values.  Thus, Charmm36 produces an accurate representation of the 




3.3.2 Structure and force field parameters for 12-crown-4 ether:  The structure of 12-crown-4 
ether was taken from PubChem compound library (CID: 9269)
 44 
 and is shown in Figure: 3.1C.  The 
12-crown-4 is a cyclic tetramer of ethylene oxide; its chemical formula is C8H16O4
45
.  12-crown-4 
ether force field parameters were derived from the Charmm Additive and Classical Drude Polarizable 
Force Fields for Linear and Cyclic Ethers (ACDPFF)
 46
. ACDPFF is force field for linear and cyclic 
ether molecules and the same force field parameters for 12-crown-4 ether were used in our previous 
MD simulation work
37
. Aβ40/42 peptides are generated through a serial cleavage of amyloid 
precursor protein (APP) by β- and γ-secretase enzymes
7,47
. After cleavage, Aβ40/42 peptides are 
independent peptides, not associated with APP and contain their own N and C-terminals. In the 
present work, in the case of Aβ40, we have treated ASP-1 as an N-terminal residue and VAL-40 as a 
C-terminal. In the case of Aβ42, we have treated ASP-1 as an N-terminal residue and ALA-42 as a C-
terminal residue. 
 
Figure: 3.1A) shows the initial structure of Aβ40 Monomer in cartoon representation. The unstructured region 
(residue 1 to 14) has been shown in blue colour, helix region (residue 15 to 40) has been shown in red colour, B) 
shows the structure of Aβ42 Monomer in cartoon representation. The unstructured region (residue 1 to 7) has 
been shown in blue colour; helix one region (residue 8 to 25) has been shown in red colour and helix two 
regions (residue 28 to 38) has been shown in green colour. Cα atoms of His14, Asn27, and Gly37 used in angle 
calculation have been represented in VdW representation for both peptides in white colour. C) shows the 
structure of 12-crown-4 in cpk  representation, 
3.3.3 Simulation Protocol:  The system, in the presence of the 12-crown-4, contains one Aβ40 
monomer, two 12-crown-4 molecules, and 8979 water molecules. In the absence of 12-crown-4, Aβ40 
monomer system contains 8993 water molecules.  The system of 12-crown-4 with Aβ42 monomer 
contains two 12-crown-4 molecules with one Aβ42 monomer and 10658 water molecules.  The Aβ42 
34 
 
monomer system, in absence of 12-crown-4, contains 9025 water molecules. Three Na
+
 counter ions 
were added into all systems to achieve overall charge neutrality. Initially, 5000 steps of steepest 
descent were performed to energy minimize the systems
48
, followed by two sequential 100ps 
equilibration simulations, first in the canonical (NVT) ensemble, then the isobaric-isothermic (NPT) 
ensemble; NPT ensemble was used for the production simulations. The bond lengths from heavy 
atoms to hydrogen atoms, of the Aβ40 and Aβ42 monomers and 12-crown-4, were constrained using 
the LINCS algorithm
49
 and the SETTLE algorithm
50
  was used for water molecule bond length 
constraints.  Particle mesh Ewald (PME)
51
 was used for long-range electrostatics and van der Waals 
(vdW) interactions with a short-range cut-off of 10Å.  In both systems (Aβ40 and Aβ42) Aβ peptide 
and non-protein components (water, 12-crown-4, and ions) were separately coupled with external 
pressure and temperature baths. The velocity-rescale algorithm
52
  was used for temperature coupling 
and the Parrinello−Rahman algorithm was used for pressure coupling 
53
.  Temperature and pressure 
bath coupling times were set to 0.1 and 0.1 ps respectively.  All MD simulations were performed at a 
pressure of 1 bar and temperature of 300K.  
  A total of eleven control simulations were performed, one (2 μs), four (200 ns) and six (100 
ns), to explore the conformation change in Aβ40 monomer in the absence of 12-crown-4; a total of 
sixteen simulations were performed in the presence of 12-crown-4 for 12-Aβ40 monomer system, one 
(2 μs), five (200 ns) and ten (100 ns).  For Aβ42 monomer system two simulations were performed, 
one in the presence of 12-crown-4 and other in the absence of 12-crown-4; each simulation was 2 μS 
long, in total of 4 μS simulations were performed for the Aβ42 system. In both systems, Aβ40 and 
Aβ42, one 12-crown-4 molecule was placed near to the N-terminal and the other 12-crown-4 
molecule was placed near to the C-terminal of Aβ40 monomer.  No prior contacts were formed 
between Aβ40 and Aβ42 monomer residues and 12-crown-4. 
3.3.3 Analysis details 
Changes in the conformational topology of the Aβ40 and Aβ 42 peptides was measured via the angle 
of the α-carbon atoms of HIS14, ASN27, and GLY37 (Figure: 3.1A, B). Aβ peptide has been 
considered in “U-shaped” if angle value is 60° or less. The number of water molecules has been 
calculated within 3.5 Å of Lys28 and Val24 residues, using an in-house Tcl script. For H-bond 
calculations the cut-off distance, between donor and acceptor atoms, was set at 3.5 Å and the angle 
was considered to be 30°. To understand the dynamics of  Lys28 (backbone and sidechain) and the 
effect of 12-crown-4 binding on its dynamics, we divided the trajectory into 10 ns bins and calculated 
the average structure for that bin;  using the average structure as reference with the “fit none” option 
of  the Gromacs RMS program, RMSD was calculated and averaged for each bin. To investigate 
conformational entropy of  Lys28 ( Backbone and sidechain), the mass-weighted covariance matrix 
was calculated, which was used for quasi-harmonic approximation
54
. Conformational entropy was 
calculated and averaged for each 10ns bin. An interaction between 12-crown-4 and Aβ peptides 
35 
 
residues were considered when the distance, between the COM of the residues and COM of 12-
crown-4, was 10 Å or less. The percentage of contact of Aβ monomers for each residue with 12-
crown-4 was calculated by counting the number of times an interaction occurred. Interaction energy 
between Aβ peptides residues and 12-crown-4 was calculated by using g_mmpbsa tool
55 
. Secondary 
structure analysis for Aβ40 and Aβ42 monomers were performed using the dictionary secondary 
structure of protein (DSSP)
56
.  The GROMACS
57
 sham program was used to construct the free energy 
contour maps and RMSD (backbone atoms) and  Rg (backbone atoms) of Aβ peptides were used as an 
order parameter to determine free energy (kJ/mol). The initial NMR structure was used for calculating 
the RMSD (backbone atoms) and Rg (backbone atoms) for in the presence of absence of 12-crown-4, 
free energy contour maps. 
3.4 Results  
3.4.1 Conformational transition of Aβ40 and Aβ42 in “U-shaped” structure and loss and 
gain of water around turn region residue Val24 and Lys28  
To investigate the conformational transition for the Aβ40 monomer from the native “I-shaped” 
structure to the “U-shaped structure” and Aβ42 monomer from the “L-shaped” structure to “U-shaped 
structure” in the presence and absence of 12-crown-4, we calculated angle of bending for all 
simulation trajectories (see the method section for more details). It has been reported that the turn 
formation in Aβ peptide is the first step toward the formation of the misfolded structure and NMR and 
MD simulations studies have suggested that Val24-Lys28  is the most probable region to form a turn
8, 
11
.  Another study, however, has suggested that a turn could also form at residue positions Glu22-
Asp23
58
.  Visual inspection of 11 control trajectories including the 2 μs long of Aβ40 monomer 
revealed that in six simulations the turn formed between residues Val24-Lys28, in two of the 
simulations the turn formed at residue position Gly29, and in one simulation the turn was formed at 
residue position Gul22-Asp23.  Visual inspection of Aβ42 monomer 2 μs trajectory revealed that the 
turn was formed around Val24-Lys28. 
To investigate the effect of water molecules on Aβ40 and Aβ42 peptides, on turn formation, 
we calculated the number of water molecules within 3.5Å of turn region residues. In a total of 11 
control simulations for Aβ40 monomer, in 6 simulation trajectories we observed loss of water 
molecules around residue Val24 and in four simulation trajectories, we observed gain of water 
molecules around Lys28. In four simulation trajectories we observed loss and gain of water molecules 
occurring at the same time in Aβ40 monomer system. In case of Aβ42 monomer, we also observed 
gain and loss of water molecules around Val24-Lys8 residues. The same phenomenon was observed 
in the long trajectories of Aβ40 and Aβ42 monomers in the presence of 12-crown-4, where turn 




Figure: 3.2A and 3.2C show the time evolution of the change in angle of Aβ40 and Aβ42 monomer, 
and Figure: 3.2B and 3.2D show the time evolution of gain and loss of water molecules around Lys28 
and Val24 in two of the representative 2 μs long trajectories of Aβ40 and Aβ42 in absence of 12-
crown-4. To understand the mechanism of turn formation, we have plotted the change in angle and 
gain/loss of water for the initial 600ns, until water gain stabilized and the peptide remained stable in 
“U-shaped” structure. The change in angle of Aβ40 monomer was observed at ~320 ns (Figure: 3.2A) 
when the peptide changed from native “I-shaped” conformation to “U-shaped” conformation. The  
peptide was considered in “U-shaped”  when angle was 60° or less; in the meantime we observed 
there was a sudden gain of water molecules around Lys28 (Figure: 3.2B, red line, Table: 3.1) and loss 
of water molecule around Val24 (Figure: 3.2B, black line, Table:1). On average there was a gain of 
~0.907 water molecules around Lys28 and a loss of ~1.275 water molecules around Val24 after “U-
shaped” structure formation in the Aβ40 monomer representative simulation. 
In Aβ42 monomer, during the transition from “L-shaped” (80°-120°) to “U-shaped” structure (<= 
60°), we observed an intermediate state where Aβ42 monomer obtained an “I-shaped”  
structure(~130° to ~170°).  At ~32ns, Aβ42 monomer obtained “I-shaped” structure, which leads to 
an increase of water molecules around both Lys28 and Val24 (Figure: 3.2D red and black line) and an 
increase of the angle form ~125° to ~170°.  At ~440ns (Figure: 3.2C) the Aβ42 monomer transformed 
from “I-shaped” structure to “U-shaped” structure; in the meantime, gain of water molecules around 
Lys28 and loss of water molecules around Val24 took place (Table: 1.1) On average there was a gain 
of ~1.227 water molecules around Lys28 and a loss of  ~1.631 water molecules around Val24, after 
“U-shaped” structure formation in the Aβ42 monomer simulation. Overall, this data suggest that the 




   
Figure: 3.2 A) Shows the time evoluion of  change in angle of Aβ40 monomer. B) Shows the time evolution of  
number of water molecules around Val24 and Lys28  of Aβ40 monomer. C) Shows the time evolution of change 
in angle of Aβ42 monomer. D) Shows the time evolution of  number of water  molecules  around Val24 and 








Table: 3.1 shows the average number of water molecules around Lys28 and Val24  in Aβ40 and Aβ42 
monomers in “I-shaped” and “U-shaped” conformations. In the “I-shaped” conformation,  average water 
molecules were calculated from 50 to 150 ns  time period for Aβ40 and Aβ42.  In the “U-shaped” structure,  
average water molecules were calculated for Aβ40 monomer from 400 to 500 ns and for Aβ42 monomer from 
450 to 550 ns. 
3.4.2 Hydrogen bonds (H-Bonds) formed by Lys28 Backbone in Aβ40 monomer 
To further investigate the effect of water gain around the Lys28 backbone, on the formation of the 
turn, we have calculated the number of intrapeptide H-bonds between amide H-bond donor and 
carbonyl H-bond acceptor atoms within the Lys28 region of the helix (Figure: 3.3A, black line) in one 
of the representative trajectories of Aβ40 monomer, in this trajectory turn was formed ~30ns. Before 
the turn formation, there are two H-bonds, one formed between the amide group of Lys28 and the 
carbonyl group of Val24 and the other between the carbonyl group of Lys28 and the amide group of 
Ile32 (Figure: 3.3B).  The aforementioned H-bonds are almost completely broken after the turn-
formation (Figure: 3.3D) and this indicates the importance of the intrapeptide H-bonds for 
maintaining Aβ40 peptide stability.  H-bonds, between water molecules and the backbone amide and 
carbonyl groups, replaced the intrapeptide H-bonds during the turn formation (Figure: 3.3A, red line); 
this leads us to believe that the formation of the water—backbone H-bonds provide a motivation for 
breaking the intrapeptide H-bonds and, therefore, turn-formation. 
Name of the residue  Average number of water 
molecules in “I-shaped” 
structure  
Average number of water 
molecules in “U-shaped” 
structure 
Aβ40 and  Lys28 12.27 13.18 
Aβ40 and  Val24 8.25 6.97 
Aβ42 and Lys28 12.17 13.40 




Figure: 3.3 A) Shows the time evolution of number of intrapeptide H-bonds (black line) and number of H-bonds 
formed with water molecules. B) Shows represented image of H-bonds formed by Lys28 at t=17.15ns. C) 
Shows represented image of H-bonds formed by Lys28 at t=26.99ns. D) Shows represented image of H-bonds 
formed by Lys28 at t=37.61ns.  
3.4.3 Percentage of contact of 12-crown-4 ether with Aβ40 and Aβ42 monomers 
To identify the residues of Aβ40 and Aβ42 monomers, which formed the most contacts with 12-
crown-4, we computed the percentage of contacts with each residue in 2 μs  long trajectories (Figure: 
3.4). 12-crown-4 ether formed major contacts with positively charged residues, Lys16 and Lys28, and 
N-terminal, Asp1 in Aβ40 monomer (Figure: 3.4A). 12-crown-4 ether also formed contact with 
central hydrophobic cluster residues (Phe19, Phe20), turn region residues (Ser26 and Gly29). In case 
of Aβ42 monomer, we observed 12-crown-4 formed major contacts with positively charged Lys16, N-
terminal Asp1 and central hydrophobic cluster residue Phe19 (Figure: 3.4B). This analysis revealed 
that 12-crown-4 ether  formed major contact with positively charged residue Lys in case of both 
peptides, however , we observed in case of  Aβ40 it  forms contacts with both Lys residues majorly, 
however; in Aβ42 monomer simulation,  12-crown-4 forms major contact with Lys16 and minor 
contacts with Lys28. Other than Lys28, which is one of the crucial residues in Aβ misfolding, Lys16 
has been reported to play a major role in Aβ toxicity
21
. Various studies have suggested that Lys16 can 
form a salt-bridge with Glu22, which helps to arrange Aβ into the antiparallel arrangement
59,60
. Karr et 
40 
 
.al. reveal that  Asp1 is a binding site of Cu ions
61





Figure: 3.4 A) Shows the percentage of contacts formed by 12-crown-4 with each residue of Aβ40 monomer in 
2 μs simulation trajectory. B) Show the percentage of contacts formed by 12-crown-4 with each residue of Aβ42 
monomer in 2 μs simulation trajectory. 




 performed structure-activity relationship of Aβ40 and revealed neurotoxicity in the 
primary neuronal cell; their data showed that Aβ with β-sheet structure was highly toxic and Aβ 
structure with a random coil is less toxic. To investigate effect of 12-crown-4 binding on secondary 
structure of Aβ peptides we have performed time evolution of secondary structure analysis of Aβ40 
and Aβ42 monomers in the presence and absence of 12-crown-4 (Figure: 3.5) 
In the absence of 12-crown-4, at ~600 ns we observed some part of the unstructured region was 
converted into the β-sheet and the β-bridge in Aβ40 monomer and remained stable until the end of the 
simulation ( Figure: 3.5A). The aforementioned event could be significant since a recent Aβ fibrils 
structure has revealed that the unstructured region of Aβ forms a β-sheet structure
64
.  In the presence 
of 12-crown-4, no β-sheet formation was observed in the Aβ40 peptide (Figure: 3.5B); however, there 
is a transition between helix to the coil from ~250ns to ~800ns, but Aβ40 peptide regained its helicity 
and remained stable until the end of the simulation. 
In the case of Aβ42 monomer in absence of 12-crown-4, we observed Helix 2 of the peptide (residue 
28-38) was almost completely converted into the turn and coil (Figure: 3.5C); however, in the 
presence of 12-crown-4, the helix region remained intact until the end of the simulation (Figure: 
3.5D). Overall this data suggest that binding of 12-crown-4 could affect the secondary structure 





      
Figure: 3.5 A) Shows time evolution of secondary structure of Aβ40 monomer in the absence of 12-crown-4. B) 
Shows time evolution of secondary structure of Aβ40 monomer in the presence of 12-crown-4. C) Shows time 
evolution of secondary structure of Aβ42 monomer in the absence of 12-crown-4. D) Shows time evolution of 




3.4.5 Interaction of 12-crown-4 ether with Asp1, Lys16, and Lys28 of Aβ40 monomer 
Figure: 3.6A) shows the time evolution of COM distances between 12-crown-4, with major contact-
forming residues. 12-crown-4 interactions with Aβ40 monomer, in the 2 μs long trajectory, can be 
divided into three steps; in the first step, 12-crown-4 interacted with c-terminal Asp-1 for the period of 
~343 ns (350-693 ns) (Figure: 3.6A, black line). In the second step, 12-crown-4 formed an interaction 
with Lys28 for a total time of ~307 ns (953-1260 ns) (Figure: 3.6A, green line). In the third step,  12-
crown-4 formed an interaction with Lys16 for a period of  ~ 255 ns (1390-1585 ns) (Figure: 6A, red 
line).The time evolution of interaction energies, between 12-crown-4 (Figure: 3.6B) and major 
binding residues, revealed that the interaction energy between  Asp1 and 12-crown-4 was slightly less 
negative  (~ -90 kJ/mol, Figure: 3.6B, black line) than the interaction energy of  Lys residues with 12-
crown-4 was (~ -120 kJ/mol, Figure: 3.6B, red and green line). To investigate the number of water 
molecules displaced by 12-crown-4, to bind with these residues we calculated the average number of 
water molecules around these residues before and during the binding of 12-crown-4 (Table: 3.2). It 
reveals that 12-crown-4, displaced ~3.97, ~3.518 and ~1.84 to interact with Asp1, Lys16 and Lys28 
respectively.  
Name of the residue (Aβ40 
monomer) 
Number of water  
molecules before 12-crown-
4 binding 
Number of water molecules 
during 12-crown-4 binding 
Asp-1 14.50 10.53 
Lys-16 13.04 9.52 
Lys-28 10.76 8.91 
Table: 3.2 show the average number of water molecules before and during the binding of 12-crown-4 around 
Asp1, Lys16, and Lys28. Before binding of 12-crown-4, a number of water molecules averaged from 0 to 100 
ns around each residue and during binding for Asp-1(400 to 500 ns), for Lys16  (1400 to 1500 ns) and  for 




Figure: 3.6 A) Shows time evolution of COM distances between Asp1, Lys16 and Lys28 from COM of 12-
crown-4. B) Shows time evolution of interaction energy between 12-crown-4 and Asp1, Lys16 and Lys28. C) 
Shows three snapshots form 2 μs trajectory of Aβ40 monomer taken at different time points, during 12-crown-4 
binding with major contact forming residues. 
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3.4.6 Interaction of 12-crown-4 ether with Asp1, Lys16, and Phe19 of Aβ42 monomer 
 Aβ42 monomer simulations with 12-crown-4 revealed that 12-crown-4 formed major contacts with 
Asp1, Lys16, and Phe19 residues. In 2 μs long simulation of Aβ42 monomer with 12-crown-4, we 
observed attachment and detachment of 12-crown-4 with these residues at different time points. 12-
crown-4 interacted with Asp1 for a total period of ~160 ns in two points of time (166-276 ns, 1230-
1280 ns) (Figure: 3.7A, black line). 12-crown-4 interacted for a total of ~506 ns with Lys16 at four 
different time points (87-142 ns, 285-374 ns, 463-740 ns, 985-1070 ns) (Figure: 3.7A, red line). 
During its interaction with Lys16, 12-crown-4 also formed interaction with central hydrophobic 
cluster residue Phe19 (Figure: 3.7A, green line). In vitro studies have suggested that a substitution of 
Lys16 for Ala in Aβ1-28
65
 and a substitution of Phe19 or Phe20 for Ala, in Aβ10-23
66
 results in the 
inability for peptides to form Aβ fibril like structures.  As for the nature and strength of the 
interactions of 12-crown-4 and Asp1, Lys16 and Phe19, the 12-crown-4 formed hydrophobic 
interactions with Phe19 (~8 kJ/mol, Figure: 3.7B, green line) and formed electrostatic interactions 
with Lys28 and Asp1 (~120 kJ/mol, Figure: 3.7B, red line, ~90 kJ/mol, Figure: 3.7B, black line). To 
investigate how many water molecules 12-crown-4 has to displace to form interaction with major 
binding residues, we have calculated average water molecules around these residues before and 
during 12-crown-4 (Table: 3.3) 12-crown-4 displaced  ~4.24, ~4.87 and ~0.0792  water molecules 
around Asp-1, Lys16 and Phe19 respectively to form the interaction with these residues. 
Name of the residue (Aβ42 
monomer) 
Number of water  
molecules before 12-crown-
4 binding 
Number of water molecules 
during 12-crown-4 binding 
Asp-1 14.62 10.38 
Lys-16 11.66 6.79 
Phe-19 12.06 11.99 
Table: 3.3 show the average number of water molecules before and during the binding of 12-crown-4 around  
Asp-1, Lys16, and Phe19. For Asp-1 before binding of 12-crown-4, a number of water molecules averaged from 
50 to 150 ns and during binding from 170 to 270 ns. For Lys16 and Phe19 before binding of 12-crown, a 
number of water molecules averaged from 0 to 60 ns and during binding 300 to 360 ns. 
In all the simulations we observed that 12-crown-4 binds with Aβ residues for certain periods of time 
and detaches; however; after detachment we have again observed binding with the same residues, 
suggesting attachment and detachment of 12-crown-4 with Aβ residues is a spontaneous process. 
There could be several factors that could contribute to its detachment; for example, 1) Change in the 
conformation of binding residues. 2) Perturbation of water structure around the binding residue. 3) 




Figure: 3.7 A) Shows time evolution of COM distances between Asp1, Lys16 and Phe19 from COM of 12-
crown-4. B) Shows time evolution of interaction energy between 12-crown-4 and Asp1, Lys16 and Phe19. C) 
Shows three snapshots form 2 μs trajectory of Aβ42 monomer taken at different time points, during 12-crown-4 
binding with major contact forming residues. 
3.4.7 Free energy landscape of Aβ40 and Aβ42 monomers in absence and presence of     
12-crown-4 
To investigate the effect of 12-crown-4 on misfolding of Aβ monomers, we have plotted two- -
dimensional free energy contour maps as a function of RMSD and RG, in the absence and presence of 
12-crown-4, as shown in Figure: 3.8 and  Figure: 3.9  with representative structures at each local free 
energy basin. In the absence of 12-crown-4 (Figure: 3.8A), there was large conformational space 
explored by the Aβ40 monomer in comparison to the presence of 12-crown-4 (Figure: 3.8B).  In the 
absence of 12-crown-4, we observed two highly populated states of Aβ40 monomer on free energy 
surface, one native-like structure state and other another one “U-shaped” structure with β-sheet. 
However, in presence of 12-crown-4 (Figure: 3.8B), there were three most populated energy states. 
One native-like structure state and  two  “U-shaped” structures with intact unstructured regions.  
 In the absence of 12-crown-4 the unstructured region adpoted the β-sheet structure, which  made it 
much less flexible and more compact, compared to the structure in the presence of 12-crown-4.  It 
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should be noted that in the absence of 12-crown-4, the number of states in the transition between the 
“I-shaped” and  “U-shaped”   structure are far greater than in the presence of 12-crown-4.  A low 
number of states in the transition region leads to an entropy barrier to transition between the  “I-
shaped” and “U-shaped” structure, and therefore, a decrease in the opportunity for transition, in the 
presence of 12-crown-4. 
 
 
Figure: 3.8 A) free energy landscape of Aβ40 monomer in the absence of 12-crown-4. B) Free energy landscape 
of Aβ40 monomer in the presence of 12-crown-4. 
In Aβ42 monomer, the free energy landscape, in the absence of 12-crown-4 (Figure: 3.9 A),  showed a 
more spread-out  profile, with two, low free energy bins; this is due to the conversion of second 
helical region into coil and turn making the structure unstable. In the presence of 12-crown-4, there is 
only one low free energy bin populated, the stable state was due to both the helix regions in Aβ42 
monomer being intact.  Overall this data suggest that the presence of 12-crown-4 affected the free 




Figure: 3.9 A) free energy landscape of Aβ42 monomer in the absence of 12-crown-4. B) Free energy landscape 
of Aβ42 monomer in the presence of 12-crown-4. 
3.4.8 Lys28 flexibility and conformational entropy in presence and absence of 12-crown-4 of 
Aβ40 monomer 
To provide a better understanding of the interplay between 12-crown-4 and Lys28, we calculated 
RMSD and conformational entropy (see the method section for more details) for Lys28 in the 
presence and absence of 12-crown-4, using the quasi-harmonic method. The function/misfolding of 
the protein is directly linked to its intrinsic flexibility; however, the intrinsic flexibility of a protein 
can be perturbed by its interaction and binding with other molecules, which could lead to a change in 
its function. Intuitively, binding between the  protein and other molecules is usually considered to 
restrict the intrinsic flexibility of the binding region in a protein and in its binding partner, which 
results in a significant loss of conformational entropy
67,68
.   
The initial RMSD value of Lys28 sidechain (Figure: 3.10A) was ~2.4 Å and increased to ~6.4 Å 
during the turn formation (30-40 ns), which consequently increased its flexibility. During the turn 
formation, the number of conformations sampled by the Lys28 sidechain drastically increased 
(Figure: 3.10A green points).  Figure: 3.10B shows the backbone and sidechain conformational 
entropy of the Lys28 in one of the representative trajectories of the control simulations (in the absence 
of 12-crown-4).  The increase in RMSD correlated with a significant gain in the conformational 
entropy of the Lys28 backbone and sidechain during the turn formation (30-40ns).  The increased 
conformational entropy of the backbone and sidechain provided a thermodynamic motivation to form 




Figure: 3.10A) Shows three representative images of Aβ40 monomer in one of the control simulations at 
different time point with RMSD values. B) Shows the QH entropy of Lys28 backbone and sidechain averaged 
for 10ns bin. Green points in the figure represent different number of state visited by the Lys28 side chain.   
To investigate how the 12-crown-4 can modify the conformation, we have performed a similar 
conformational analysis for a representative simulation in the presence of 12-crown-4.  Figure: 3.11A 
shows the RMSD of Lys28 sidechain, in the presence of 12-crown-4, at different time points in the 
simulation. Initially, from 0-10 ns, before the interaction between Lys28 with 12-crown-4, the RMSD 
value for Lys28 sidechain was ~3.00Å; during the binding with 12-crown-4, it reduced to ~1.186 Å. 
Around ~140 ns-160 ns, we again observed a loss of RMSD due to the contacts of unstructured region 
residues with the Lys28 sidechain.  Reduction in RMSD during 12-crown-4 binding resulted in loss of 
flexibility of Lys28 sidechain; this leads to significant loss of number of states visited by the Lys28 





Figure: 3.11A) Shows three representative images of Aβ40 monomer in one of  the simulations in the presence 
of 12-crown-4 at different time point with RMSD values. B) Shows the QH entropy of Lys28 backbone and 
sidechain averaged for 10ns bin. Green points in the figure represent number of state visited by the Lys28. 
Figure: 3.11B and C show the conformational entropy of  Lys28 backbone and sidechain. During the 
binding of 12-crown-4 (~30-110 ns), a significant loss of conformational entropy was observed, as 
binding of 12-crown-4 restricted the number of conformations obtained by Lys28 backbone and 
sidechain.  At a time point of ~120-160 ns, we also observed binding of the unstructured region with 
Lys28 sidechain, which resulted in a reduction of its conformational entropy.  Despite a loss of 
entropy upon binding of the 12-crown-4 and Lys28, which should be unfavourable, the attractive 
interaction between 12-crown-4 and Lys28 more than compensates.   
 
3.5 Discussion 
We have performed Aβ40 and Aβ42 monomer simulations in the presence and absence of 12-crown-
4. Our simulation data revealed that Aβ40 and Aβ42 peptide misfolding starts with the formation of 
the turn, in agreement with previous studies
8,9,10
.  In our simulations we observed the turn formation, 
around Val24-Lys28, is initiated by the gain and loss of water molecules around Lys28 and Val24 
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respectively.  Loss of water molecules around Val24 is in agreement with well-established 
“hydrophobic effect” phenomena
69
, which suggest that during the protein folding/misfolding, the 
nonpolar side chains are removed from contact with water molecules; this leads to the burial of 
hydrophobic side chains into the core of protein.   A previous study
18
  suggested that nearby non-polar 
groups dehydrate backbone hydrogen bonds, which makes it thermodynamically unfavourable to 
expose the backbone amide and carbonyl groups. Shielding the H-bonds from water molecules helps 
the protein to maintain secondary structure and warrant them overall stability. In the present study, we 
observed that the polar/hydrophobic part of the Lys28 sidechain gained a significant number of water 
molecules, which lead to the water molecules becoming more accessible to the Lys28 backbone.  At 
the same time point in the simulation, there was a significant gain of Lys28 sidechain conformation 
entropy which leads to a gain in the backbone conformational entropy.  Water gain around the Lys28 
backbone and entropy gain leads to the lengthening of the intrapeptide H-bonds formed by amide and 
carbonyl group of Lys28 backbone, and these H-bonds were replaced by water molecules, which 
destabilizes the Aβ peptide. Loss and gain of water molecules around Val24 and Lys28, 
conformational entropy gain of Lys28 and breaking of intrapeptide H-bonds are key factors, in turn 
formation/early stage misfolding of Aβ peptide.  
Our simulation data in the presence of 12-crown-4 revealed that it specifically binds to charged 
residues, Lys16, Lys28, Asp1, and Phe19. 12-crown-4 contains hydrogen and oxygen atoms, this 
helps 12-crown-4 to form electrostatic interactions with charged Lys, N-terminal Asp, and 
VdW/hydrophobic interactions with Phe19 residue. These pharmacophore features of 12-crown-4 
could be used in designing new highly specific candidate drug molecules or imaging probes. In one 
previous study, Jiang et. al.
70
  used pharmacophore features of an Aβ fragment complex with the dye 
orange G, which specifically binds with Lys16  to search new potential compounds. They identified 
eight diverse and three compound derivatives that reduced the Aβ cytotoxicity against mammalian 
cells by up to 90%. 
   Our data support the hypothesis of  Tian et. al.
35
 that 12-crown-4 can bind with positively 
charged Lys residues of  Aβ peptide and perturb its aggregation and toxicity. 12-crown-4, conjugated 
with PiB, was shown to cross BBB and inhibit the Aβ aggregation and the present study has 
highlighted the molecular-level factors with which the inhibition of aggregation may occur.  The 
present study is also in-line with previous studies which suggest that Lys specific candidate drug 
molecules could perturb the Aβ aggregation and reduce its toxicity
20,21
. Simmons et. al.
63
 study 
suggested that the Aβ peptide with β-sheet structure was highly toxic, and Aβ structure with a random 
coil is less toxic. As we observed in presence of 12-crown-4 secondary structure remained stable in 




3.6 Conclusions  
In summary, our simulations have shed light on the fundamental understating of turn formation. We 
observed the gain of water molecules around Lys28 sidechain and increase in its conformational 
entropy that leads to the break of intra-peptide H-bonds of Lys28 backbone and consequently the turn 
formation. Our data reveals that 12-crown-4, which has potential as a drug  carrier when conjugated 
with an amyloid targeting agent, is highly specific toward Lys16, Lys28 and Asp1; moreover, we 
observed contacts formed by 12-crown-4 with central hydrophobic cluster residues, Phe19 and Phe20, 
and turn region residues Ser26 and Gly29. Secondary structure analysis suggests that 12-crown-4 
binding inhibited secondary change in both Aβ40 and Aβ42 monomer. Free energy contour maps 
revealed that 12-crown-4 can restrict number of conformations explored by Aβ peptides and therefore, 
affect its misfolding.  
The present study deepens our knowledge about the molecular-level factors that contribute to the turn 
formation in early stage misfolding of the Aβ40 monomer; furthermore, it underpins the importance 
of Lys residues as potential targets for Aβ inhibition. The present study has, therefore, opened up new 
avenues in design of potential inhibitors for early stage misfolding of Alzheimer’s Aβ monomers. 
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10.1021/acs.molpharmaceut.7b00966. 
Results of gain/loss of water and binding of 12-crown-4 in Aβ40 monomer simulations (PDF) 
Movie of Aβ40 monomer in absence and presence of 12- crown-4 (AVI) 
Movie of Aβ42 monomer in absence and presence of 12- crown-4 (AVI) 
 
Funding Source: N.A. would like to thank DST-NRF, South Africa for project funding (grant 
number: 106272).  We would like to thank college of Health Sciences at UKZN for funding and 
infrastructure support. 
Notes 
The authors declare no competing financial interest. 
Acknowledgement: We are indebted to UKZN “hippo” super computer facility, Durban, South 
Africa, and Centre for High Performance Computing (CHPC) in Cape Town, South Africa for 





1. Uflacker, A.; Doraiswamy, P. M.  Alzheimer’s Disease: An Overview of Recent 
Developments and a Look to the Future. Focus 2017, 15, (1), 13-17. 
2. Association, A. s.  2016 Alzheimer's disease facts and figures. Alzheimer's & Dementia 2016, 
12, (4), 459-509. 
3. Buxbaum, J. N.  Alzheimer’s Disease: It’s More Than Aβ. The FASEB Journal 2017, 31, (1), 
2-4. 
4. Pivi, G. A. K.; de Andrade Vieira, N. M.; da Ponte, J. B.; de Moraes, D. S. C.; Bertolucci, P. 
H. F.  Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe. 
Nutrire 2017, 42, (1), 1. 
5. Jakob‐Roetne, R.; Jacobsen, H.  Alzheimer's disease: from pathology to therapeutic 
approaches. Angewandte Chemie International Edition 2009, 48, (17), 3030-3059. 
6. Mullard, A.  Alzheimer amyloid hypothesis lives on. Nature Reviews Drug Discovery 2017, 
16, (1), 3-5. 
7. Bergström, P.; Agholme, L.; Nazir, F. H.; Satir, T. M.; Toombs, J.; Wellington, H.; 
Strandberg, J.; Bontell, T. O.; Kvartsberg, H.; Holmström, M.  Amyloid precursor protein expression 
and processing are differentially regulated during cortical neuron differentiation. Scientific reports 
2016, 6. 
8. Lazo, N. D.; Grant, M. A.; Condron, M. C.; Rigby, A. C.; Teplow, D. B.  On the nucleation of 
amyloid β‐protein monomer folding. Protein Science 2005, 14, (6), 1581-1596. 
9. Baumketner, A.; Bernstein, S. L.; Wyttenbach, T.; Lazo, N. D.; Teplow, D. B.; Bowers, M. 
T.; Shea, J. E.  Structure of the 21–30 fragment of amyloid β‐protein. Protein Science 2006, 15, (6), 
1239-1247. 
10. Cruz, L.; Urbanc, B.; Borreguero, J. M.; Lazo, N. D.; Teplow, D. B.; Stanley, H. E.  Solvent 
and mutation effects on the nucleation of amyloid β-protein folding. Proceedings of the National 
Academy of Sciences of the United States of America 2005, 102, (51), 18258-18263. 
11. Borreguero, J. M.; Urbanc, B.; Lazo, N. D.; Buldyrev, S. V.; Teplow, D. B.; Stanley, H. E.  
Folding events in the 21-30 region of amyloid β-protein (Aβ) studied in silico. Proceedings of the 
National Academy of Sciences 2005, 102, (17), 6015-6020. 
12. Tarus, B.; Straub, J. E.; Thirumalai, D.  Dynamics of Asp23− Lys28 Salt-Bridge Formation in 
Aβ10-35 Monomers. Journal of the American Chemical Society 2006, 128, (50), 16159-16168. 
13. Khatua, P.; Jose, J. C.; Sengupta, N.; Bandyopadhyay, S.  Conformational features of the Aβ 
42 peptide monomer and its interaction with the surrounding solvent. Physical Chemistry Chemical 
Physics 2016, 18, (43), 30144-30159. 
14. Melquiond, A.; Dong, X.; Mousseau, N.; Derreumaux, P.  Role of the Region 23-28 in Aβ 
Fibril Formation: Insights from Simulations of the Monomers and Dimers of Alzheimer's Peptides 
Aβ40 and Aβ42. Current Alzheimer Research 2008, 5, (3), 244-250. 
53 
 
15. Fleming, P. J.; Rose, G. D.  Do all backbone polar groups in proteins form hydrogen bonds? 
Protein Science 2005, 14, (7), 1911-1917. 
16. Li, J.; Wang, Y.; Chen, J.; Liu, Z.; Bax, A.; Yao, L.  Observation of α-helical hydrogen-bond 
cooperativity in an intact protein. J. Am. Chem. Soc 2016, 138, (6), 1824-1827. 
17. Levy, Y.; Onuchic, J. N.  Water and proteins: a love–hate relationship. Proceedings of the 
National Academy of Sciences of the United States of America 2004, 101, (10), 3325-3326. 
18. Fernández, A.; Scheraga, H. A.  Insufficiently dehydrated hydrogen bonds as determinants of 
protein interactions. Proceedings of the National Academy of Sciences 2003, 100, (1), 113-118. 
19. Hernández‐Rodríguez, M.; Correa‐Basurto, J.; Benitez‐Cardoza, C. G.; Resendiz‐Albor, A. 
A.; Rosales‐Hernández, M. C.  In silico and in vitro studies to elucidate the role of Cu2+ and 
galanthamine as the limiting step in the amyloid beta (1–42) fibrillation process. Protein Science 
2013, 22, (10), 1320-1335. 
20. Sinha, S.; Lopes, D. H.; Du, Z.; Pang, E. S.; Shanmugam, A.; Lomakin, A.; Talbiersky, P.; 
Tennstaedt, A.; McDaniel, K.; Bakshi, R.  Lysine-specific molecular tweezers are broad-spectrum 
inhibitors of assembly and toxicity of amyloid proteins. Journal of the American Chemical Society 
2011, 133, (42), 16958-16969. 
21. Sinha, S.; Lopes, D. H.; Bitan, G.  A key role for lysine residues in amyloid β-protein folding, 
assembly, and toxicity. ACS chemical neuroscience 2012, 3, (6), 473-481. 
22. Marlow, M. S.; Dogan, J.; Frederick, K. K.; Valentine, K. G.; Wand, A. J.  The role of 
conformational entropy in molecular recognition by calmodulin. Nature chemical biology 2010, 6, 
(5), 352-358. 
23. Baruah, A.; Rani, P.; Biswas, P.  Conformational entropy of intrinsically disordered proteins 
from amino acid triads. Scientific reports 2015, 5. 
24. Doig, A. J.; Sternberg, M. J.  Side‐chain conformational entropy in protein folding. Protein 
Science 1995, 4, (11), 2247-2251. 
25. Frederick, K. K.; Marlow, M. S.; Valentine, K. G.; Wand, A. J.  Conformational entropy in 
molecular recognition by proteins. Nature 2007, 448, (7151), 325-329. 
26. Chia-en, A. C.; Chen, W.; Gilson, M. K.  Ligand configurational entropy and protein binding. 
Proceedings of the National Academy of Sciences 2007, 104, (5), 1534-1539. 
27. Stone, M. J.  NMR relaxation studies of the role of conformational entropy in protein stability 
and ligand binding. Accounts of chemical research 2001, 34, (5), 379-388. 
28. Li, J.; Yim, D.; Jang, W.-D.; Yoon, J.  Recent progress in the design and applications of 
fluorescence probes containing crown ethers. Chemical Society Reviews 2017. 
29. Gokel, G. W.; Leevy, W. M.; Weber, M. E.  Crown ethers: sensors for ions and molecular 
scaffolds for materials and biological models. Chemical reviews 2004, 104, (5), 2723-2750. 
54 
 
30. Marjanović, M.; Kralj, M.; Supek, F.; Frkanec, L.; Piantanida, I.; Šmuc, T.; Tušek-Božić, L.  
Antitumor potential of crown ethers: structure− activity relationships, cell cycle disturbances, and cell 
death studies of a series of ionophores. Journal of medicinal chemistry 2007, 50, (5), 1007-1018. 
31. Morrison, P. W.; Porfiryeva, N. N.; Chahal, S.; Salakhov, I. A.; Lacourt, C.; Semina, I. I.; 
Moustafine, R. I.; Khutoryanskiy, V. V.  Crown Ethers: novel permeability enhancers for ocular drug 
delivery? Molecular Pharmaceutics 2017, 14, (10), 3528-3538. 
32. Oukhatar, F.; Même, S.; Même, W.; Szeremeta, F. d. r.; Logothetis, N. K.; Angelovski, G.; 
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4.1 Abstract  
Recent experimental data elucidated that 12-crown-4 ether molecule can disrupt Aβ40 fibrils but the 
mechanism of disruption remains elusive. We have performed a series of all-atom molecular 
dynamics simulations to study the molecular mechanism of Aβ40 fibril disruption by 12-crown-4.  In 
the present study we have used the Aβ40 fibril trimer as it is the smallest unit that maintains a stable 
U-shaped structure, and serves as the nucleus to form larger fibrils.  Our study reveals that 12-crown-
4 ether can enter into the hydrophobic core region and form competitive, hydrophobic interactions 
with key hydrophobic residues; these interactions break the inter-sheet hydrophobic interactions and 
lead to the opening of the U-shaped topology and a loss of β-sheet structure.  Furthermore, we 
observed periods of time when 12-crown-4 was in the hydrophobic core and periods of time when it 
interacted with Lys28 (chain C), a "tug of war"; the 12-crown-4 binding with Lys28 destabilizes the 
salt-bridge between Asp23 and Lys28. In addition to the two aforementioned binding modes, the 12-
crown-4 binds with Lys16, which is known to form a salt-bridge with Glu22 in antiparallel arranged 
Aβ fibrils. Our results are in good agreement with experimental results and suggest that molecules 
that have the ability to interact with both the hydrophobic core region and positively charged residues 














AD is caused by misfolding and aggregation of amyloid beta (Aβ) peptide, into 
amyloid-β-fibrils (Aβ fibrils) and affects the structure and function of neural cells leading to synaptic 
dysfunction
3,4
. It has been reported that cytotoxicity of Aβ fibrils depends on its morphology and 
remodeling of Aβ fibrils can significantly reduce its cytotoxicity
5
. Understanding the mechanism of 
amyloid genesis and disruption allows us to design more effective ways of controlling the disease. 
Crown ethers are small, cyclic polyethers that work as cation chelators, and this property of crown 
ethers has been extensively used in phase-transfer catalysis and in the activation of proteins in organic 
solvents
6,7,8
. A recent study by Tian et al
9
 proposed a new strategy to attenuate the aggregation of Aβ 
through a non-covalent modification at the protein surface. Their experimental results showed that the 
12-crown-4 ether caused a reduction in the zeta potential of Aβ40 fibrils, once it was mixed with the 
12-crown-4 ether (from -48 mV to -4 mV); this pointed to a reduction in the surface charge upon 
binding.  In addition, anti-aggregation testing results revealed that the presence of 12-crown-4 can 
reduce the aggregation of Aβ40 peptides in fibrils. Transmission electron microscopy (TEM) images 
revealed that Aβ40 fibrils, formed in the presence of 12-crown-4, had a different morphology than 
those in the absence of 12-crown-4 and this could be significant since different morphologies of Aβ 
fibrils relate to different cytotoxicity
5
. The authors hypothesized that 12-crown-4 interacts with 
positively charged residues (Lys, Arg, His) and this could attenuate Aβ40 peptide aggregation and 
affect Aβ fibril conformation.
 
In another experimental study, Lee et al.
10
 co-crystallized 18-crown-6 ether with several protein 
structures and revealed that crown ether specifically interacted with the hydrophobic patches, or with 
the amine group of  Lys; this resulted in dramatic alterations to the protein surface.  Das et al.
11
 
revealed by a mutation study that contact between Phe19 and Leu34 are critical for the formation of 
Aβ40 oligomer; their study showed that altering this interaction drastically reduced the cytotoxicity of 
Aβ40 oligomers. Chandrakesan et al.
12
 showed by a Nuclear magnetic resonance spectroscopy (NMR) 
study that contact between Phe19 and Leu34  plays a crucial role in self-assembly of Aβ fibrils and 
they suggested that candidate drug molecules, with the ability to disrupt the contact between Phe19 
and Leu34, are expected to have a very strong effect on the aggregation of Aβ.  
In the present molecular dynamics study, the Aβ40 fibril single trimer unit is used and is shown in 
Figure: 4.1A; this was taken from the experimental structure formed by three trimeric units (PDB: 
2M4J), arranged in three fold symmetry. The particular structure was chosen over other available 
experimental structures of Aβ40 fibrils because this is the first detailed, experimentally determined 
structure of any patient brain-derived Aβ aggregate
13
.  The Aβ40 fibril structure contains an N-
terminal disordered region (residues 1-10), two β-sheets (residues 11-19, and residues 31-38), and a 
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connecting region. The bend, in the connecting region of two β-sheets in Aβ fibrils, brings the two-
sheets in contact through side chain interactions, which leads to a double-sheet structure (U-shaped 
structure) with a core region (residues 17-36), Figure: 4.1B.  The core region can be subdivided into 
three parts: (1) side chains of Leu17, Phe19, Ala 21, Ile 31, Leu34, and Val36 that form hydrophobic 
interactions. (2) Side chains of residues Ala 29, Gly30, Ile 32, Gly33, and Met35 face toward the 
outside and form the hydrophobic face. (3) Side chains of Asp23 and Lys28 form a salt bridge, which 
plays a crucial role in Aβ fibrils stability
13,14
. 
Previously, several MD simulation studies have been conducted on the interaction between Aβ fibrils; 
for example, Lemkul et al.
15
  has shown that an organic molecule, Morin, can enter into the 
hydrophobic core and destabilize the salt bridge formed by Asp23-Lsy28.  Another study by Tianhan 
Kai et al.
16
 has revealed that Tabersonine can interact with β-sheet grooves containing aromatic and 
hydrophobic residues, which they postulate could affect the elongation process;  however,  in both of 
these studies they did not observe the opening of the U-shaped structure of Aβ fibril.  To the best of 
our knowledge no molecular dynamics study of Aβ fibril and an organic molecule has shown the 
complete opening of the U-shaped topology of Aβ fibril.  
In the present study, we aim to find a molecular basis for the Aβ40 fibril remodelling by 12-crown-4. 
Specifically, the following questions still need to be answered (1) which region does 12-crown-4 bind 
to?  (2) Is there any region on Aβ40 fibril that is particularly favourable or unfavourable for 12-
crown-4 binding? (3) What is the impact of 12-crown-4 binding on the conformation of the Aβ40 
fibril? To address all these questions we have performed more than 25 all-atom molecular dynamics 
simulations of Aβ40 fibrils in the presence and absence of 12-crown-4 and investigated the 
mechanism of Aβ40 disruption by 12-crown-4 ether molecule. 12-crown-4 ether structure has been 
shown in Figure: 4.1C 




   
Figure: 4.1 A) Shows the initial structure of Aβ40 fibril containing disordered region (1-10) in green color, β-
sheet-1 in blue color (11-19),  connecting region in orange color (20-30) and β-sheet-2 in red color (31-38). The 
Aβ40 fibril trimer is shown in cartoon representation. B) Shows core region residues in liquorice representation 
colored by residue type: hydrophobic residues (white), negatively charged residues (red), positively charged 
residues (blue), and polar residues (green). C) Chemical structure of 12-crown-4 molecule. 
 
4.3 Results and Discussion 
4.3.1 Insertion of 12-crown-4 in core region and opening of U-shaped structure Aβ40 fibril 
Out of a total of 15 independent simulations, 8 simulations showed the spontaneous entering of 12-
crown-4 into the core region; in 6 simulations 12-crown-4 interacted with aromatic and hydrophobic 
residues, was highly stable and an opening event occurred. In all control simulations, the RMSD and 
“opening” of Aβ40 fibril remained stable and U-shaped topology remained intact (Figure: 4.1S). 
Figure: 4.2A shows the time evolution, in one of the representative trajectories, of “entering” of 12-
crown-4 in the core region of Aβ40 fibril and U-shaped structure “opening” (see method section for 
details). Figure: 4.2B shows the change in Aβ40 fibril conformation, monitored by RMSD of residue 
11 to 40 backbone atoms. The atomic level representation of the mechanism of entering of 12-crown-





Figure 4.2: A) Shows time evolution of “entering” of 12-crown-4 in core region (red line) and “opening” of U-
shaped structure of Aβ40 fibril (black line). B) Shows time evolution of conformational change in Aβ40 fibrils. 
 
 
Figure 4.3: Four representative structures taken at different time points in a representative trajectory A) Entering 
of 12-crown-4 in core region (16.72ns) and making competitive hydrophobic interaction with top and bottom β-
sheets residues.  B) 12-crown-4 working as a bridge between side chains of top and bottom β-sheets residues 
(21.70ns).  C) Opening of U-shaped topology (22ns).  D) 12-crown-4 left the core region. 
 
In step-A, 12-crown-4 enters into the core region at ~16.72 ns, as shown by a decrease in the 
“entering” value (Figure: 4.2A, red data set); at this time point, competitive interactions were 
established between 12-crown-4 and, the aromatic and hydrophobic residues of the two opposing β-
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sheet residues.  In step-B, a bridge is formed between two opposing β-sheet hydrophobic residues 
(~21.7 ns) (Figure: 4.3B).  In step-C, the 12-crown-4/hydrophobic bridge eventually breaks and the 
two opposing β-sheets do not have the opportunity to reconnect, an opening event occurs (Figure: 
4.3C); this results in an increase in the “opening” value (Figure: 4.2A, black data set) and a large 
increase in RMSD value at 22 ns (Figure: 4.2B).  The 12-crown-4 remained bound to the top β-sheet 
(β-sheet-1) residues for duration of ~2 ns. At ~24 ns there is separation of 12-crown-4 with the core 
region (Figure: 4.3D). 
4.3.2 Deciphering the core region contact sites of 12-crown-4 
Now we have observed an event we try to elucidate the mechanism for Aβ40 fibril opening as it is 
desirable to gain an understanding of the specific interactions and driving forces at play during this 
process. Figure: 4.4A shows the average distances of all three peptide residues from the COM of 12-
crown-4; this illustrates the specific interactions of 12-crown-4, after insertion, in the core region (16 
ns to 24 ns).  Residues in β-sheet-1 (Leu17 and Phe19) and residues in β-sheet-2, (Ile31, Leu34 and 
Val36) form a close contact with 12-crown-4 (less than 5 Å).  The five aforementioned side chains 
face each other and form a hydrophobic core (Figure: 4.4B) that plays an important role in 
maintaining the U-shaped structure of Aβ40 fibril.  For further understanding, we calculated the time 
evolution of the average distance of these residues from the COM of 12-crown-4, during the binding, 
for all three peptides (Figure: 4.4C). It is revealed that 12-crown-4 first interacts with the bottom β-
sheet residues, Leu34, Ile31 and Val36.  At the time of bridging and opening (steps B and C), there 
are increases in the bottom residue―12-crown-4 distances and decreases in the top residue―12-
crown-4 distances; these changes occur as 12-crown-4 remains bound to the top residues before 
completely separating.  
 Time evolutions of the interaction energy between top (Leu17, Phe19) and bottom residues (Leu34, 
Val36) (black data set, ΔEtop―bottom) and the interaction energy of 12-crown-4 with both top (red data 
set, ΔEtop―crown) and bottom residues (green data set, ΔEbottom―crown), are shown in Figure :4D.  Before 
binding, ΔEtop―bottom is attractive (~ -22 kJ/mol) and at ~14 ns, ΔEtop―bottom becomes less negative 
when there is a momentary 12-crown-4 interaction.  When 12-crown-4 fully enters, at step-A, 
ΔEtop―bottom is ~ -22 kJ/mol, similar to that of the unbound ΔEtop―bottom value; however, binding of 12-
crown-4 causes ΔEtop―bottom to become less negative (~ -13.5 kJ/mol), indicating the role of 12-crown-
4 in weakening the interaction between top and bottom residues. When bridging starts, at step-B, 
ΔEtop―bottom becomes less attractive, becoming zero at step-C; at this point in time, ΔEbottom―crown 
abruptly goes to zero as opening starts.  ΔEtop―crown, however, remains the same at step-C and this 
value only goes to zero at step-D, as 12-crown-4 completely leaves the core region. 
As stated, before entering of 12-crown-4, ΔEtop―bottom is comparable to ΔEtop―crown and ΔEbottom―crown.  
When taken together ΔEtop―crown and ΔEbottom―crown (~-24 kJ/mol + ~ -23 kJ/mol = ~-47 kJ/mol) far 
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exceeds ΔEtop―bottom (~-22 kJ/mol); this provides an energetic basis for the competition between 12-




Figure: 4.4: A) The average distance of 12-crown-4 from all three peptide residues during binding (16-24ns). B) 
The closest distance residues, during binding time, in CPK model and protein has been shown in new cartoon 
reprsentation. C) Time evolution of distance from closest residues. D) Shows the interaction energy between top 
and bottom β-sheets residues (ΔEtop―bottom),  interaction energy between top β-sheet and 12-crown-4 
(ΔEtop―crown)  and bottom β-sheet and 12-crown-4 (ΔEbottom―crown) . 
 
4.3.3 Secondary structure changes 
It has previously been shown that the  structural stability of the Aβ40 fibril is directly associated with 
the β-sheet content
17,18
. To investigate the effect of opening of the U-shaped structure on the 
secondary structure content, we extended one of the simulations for a longer time period; in this 
simulation opening took place at 10ns.  We calculated the time evolution of the secondary structurre 
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in the bottom β-sheet residues of all three peptide for control (Figure: 4.5 A) and 12-crown-4 (Figure: 
4.5 B) simulations.   
 
Figure: 4.5 A) Left panel shows representative structure from control simulations at 300ns, and time evoluation 
of secondary structure change in bottom β-sheets in all three peptides. B) Right panel shows representative 
structure of  Aβ40 fibril with 12-crown-4 simulation at 300ns, and time evoluation of secondary structure 
change in bottom β-sheets residues of all three peptides. 
In the control simulation, the content of β-sheet and coil always remained quiet stable and no α-helix 
formation was observed; howerver, during the time period between 100-150ns subtle transition were 
obesrved in β-sheet structute of chain A  residues between 32 to 35 in to coil. After that time period 
they gained there β-sheet content again. In the simulation, in the presence of 12-crown-4; however, 
we obseved a reduction in β-sheet content and increase  in coil content after opening.  After ~50ns α-
helix content started to form and this stablized after ~150 ns, when ~4 residues  maintained the α-
helix stucture until the end of the simulation.  These results unequivacally show that the 12-crown-4 
has not only caused an opening event but when the Aβ40 fibril does open the conformation changes. 
The result of the conformational changes is that the bottom residues should no longer be able to 
accommodate  the U-shaped structure; therefore, the recombination of top and bottom sheets would 
require a further comformational change, which should take more time and make this process more 
unfavorable.      
4.3.4 Tug of war of 12-crown-4 between hydrophobic core and Lys28 
Since 12-crown-4 contains both oxygen and hydrocarbon groups, it should be able to from both 
hydrogen bonding/electrostatic interactions with hydrophilic groups and, van der Waals/hydrophobic 
interactions with hydrophobic residues.  This amphiphilic behaviour was observed in two simulations, 
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where 12-crown-4 entered into the core region yet no opening event took place; however, we obseved 
periods of time when the 12-crown-4 was in the hydrophobic core and periods of time when it 
interacted with Lys28 (chain C),  a "tug of war" (Figure: 4.6A). First, 12-crown-4 entered into the 
core region, in a similar fashion to that described above; it entered at ~12 ns and stayed there until 
~33ns (Figure : 4.6C, green line). At ~33 ns, 12-crown-4 shifted towards Lys28 of chain C and 
formed hydrogen bonds (Figure: 4.6B, Figure: 4.6C, black line);  this broke the salt-bridge formed by 
Aps23 and Lys28 (Figure: 4.6 C, red line).  At ~70ns the 12-crown-4 broke contract with Lys28, the 
salt bridge reformed and the 12-crown-4 shifted back to the hydrophobic core region.  At ~75ns the 
12-crown-4 left the hydrophobic region and in fact the whole Aβ40 fibril.   
To understand the enegetic interplay between 12-crown-4 binding with Lys28 and the hyrophobic 
core, we calculated the time evolution of the interaction energy between 12-crown-4 and Lys28 
(ΔELys28―crown), the interaction between 12-crown-4 and the hyrophobic core residues 
(ΔEhydrophobic―crown) and the interaction energy between Asp23 and Lys28 (ΔEAsp23―Lys28); these are 
shown in Figure: 4.6D, black, green and red lines, respectively.  The 12-crown-4 interacts with the 
hyrophobic core resulting in the ΔEhydrophobic―crown value of ~-53 kJ/mol and when 12-crown-4 shifts to 
Lys28, it strongly interacts with a ΔELys28―crown  value of ~-230 kJ/mol.  At the start of the simulation, 
when the salt bridge is fully formed,  ΔEAps23-Lys28 is hugely attractive at ~ -410 kJ/mol (Figure: 4.6D 
red);  12-crown―Lys28 interaction, however, destablizes the salt-bridge interaction, making ΔEAsp23-
Lys28 less favorable (~ -220 kJ/mol).  It should be noted that ΔELys28―crown was much higher than 
ΔEhydrophobic―crown;  there could be three possibile reasons that 12-crown-4 shifted back to the 
hydrophobic core (1) There are a greater number of  residues in the hyrophobic core, so  12-crown-4 
has a greater opporunity to interact. (2)  There is competition between Asp23 (salt-bridge) and 12-
crown-4 for binding to Lys28.  (3) There is greater competition of  Lys28 with water molecules than 
that of the hydrophobic residues.  In order to bind to Lys28, 12-crown-4 must displace ordered water 
molecules that are hydrogen bonded to the -NH3
+ 
group (on average a reduction of 1.50 water 
molecules in the first solvation shell, see Table: 4.1S).  The number of water molecules that are 
displaced is far fewer for the hyrophobic resdues; for example, on average there is a reduction of 0.04 




Figure: 4.6 A) Shows the representative structure of  12-crown-4 with hyrophobic core residues during binding. 
B) Shows the representative structure of 12-crown-4 with Lys28 chain C during binding. C) Shows the distance 
of 12-crown-4 from hyrophobic core, 12-crown-4 and Lys28 distance and salt-bridge distance between Asp23 
and Lys28. 
 
4.3.5 Interaction with Lys16 
Various studies have shown that Lys16 and Glu22. with their opposite positive and negative charges, 
form electrostatic interactions and this favours the Aβ fibrils arrangement in-register antiparallel 
alignment
19
.  An interaction of 12-crown-4, with either Lys16 or Glu22, should therefore, hinder such 
alignment, decreasing the extent of amyloid fibril formation; 12-crown-4 interaction with Lys16 was, 





Figure: 4.7 A) Shows the representative structure of 12-crown-4 bound on Aβ40 fibrils. B) Shows the time 
evolution of distance between 12-crown-4 and Lys16 of chain B. C) Shows the time evolution of interaction 
energy between 12-crown-4 and Lys16 of chain B. 
Figure: 4.7A shows the Lys28―12-crown-4 distance and Figure: 7B shows the interaction energy 
between Lys 28 and 12-crown-4 (ΔELys16―crown).  12-crown-4 binds to Lys16 at ~22 ns and remains 
bound until ~76 ns (for ~ 45 ns).   The ΔELys16―crown value was ~ -230 kJ/mol during the binding, 
which is similar to that of ΔELys28―crown. 
To bind to Lys16, 12-crown-4 needs to displace, on average, 2.7 water molecules from the first 
solvation shell (supplementary table: 4.1S).  The number of water molecules that get displaced is 
greater for Lys16 than for Lys28 because, in the absence of 12-crown-4 interaction, there are more 
water molecules available to interact with Lys16 (4.62 water molecules) than for Lys28 (3.27), 
Figure: 4S, 5S; this is because part of the coordination of Lys28 is taken up by the salt-bridge between 
Asp23 but Lys16 is not engaged in a salt-bridge.  The amount of structured water molecules, around –
NH3
+
, after coordination with 12-crown-4 is comparable for Lys16 and Lys28 (approximately 1.8 
water molecules on average) since the 12-crown-4 causes a break in the Asp23-Lys28 salt-bridge. 
4.3.6 Binding free energy and energetic contribution  
The binding free energy of 12-crown-4 with Aβ40 fibril (ΔGtotal) was evaluated by the MM-PBSA 
method (see the method section for more details), during the time of 12-crown-4 binding with Aβ40 
fibril for all three binding modes (Table: 4.1).  The contribution to ΔGtotal from van der Waals and 
electrostatic interactions is denoted ΔEvdw and  ΔEelec.  Polar and nonpolar contributions to ΔGtotal have 
been denoted by ΔGpolar and ΔGnon-polar, respectively.  As expected, Mode-3 and Mode-2/Lys28 have 
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greater overall binding than Mode-2/hydrophobic and Mode-1. Since, in Mode-1 and Mode-
2/hydrophobic, the binding contains hydrophobic residues, the Van der Waals energy is the most 
favourable contributor; however, the electrostatic energy is the most favourable contributor in Mode-
2/Lys28 and, Mode-3/Lys16. The ΔGpolar value, which is always unfavourable for the 12-crown-4-
Aβ40 fibril complexes, is less unfavourable in case of the hydrophobic core binding sites compared to 
Lys binding sites.  For the latter case, the total gain in intermolecular electrostatic interaction 
















  ΔEvdw -58.28 ± 0.95 -62.83 ± 0.57 -41.69 ± 0.88 -22.11 ± 0.64 
ΔEelec -1.76 ± 0.73 -12.72 ± 1.47 -214.56 ± 2.04 -230.34 ± 1.41 
ΔGpolar 20.02 ± 0.63 31.41 ± 1.15 160.47 ± 1.24 150.15 ± 0.99 
 ΔGnon-polar -9.63 ± 0.12 -10.25 ± 0.07 -9.51 ± 0.10 -6.031 ± 0.05 
ΔGtotal -49.63 ± 1.18 -54.43 ± 0.99 -105.36 ± 1.27 -108.22 ± 0.76 
Table: 4.1 Average binding energy and its components obtained from the MM-PBSA calculations for Aβ40 
fibril-12-crown-4 complex, all energies are in kJ/mol. 
To gain even more detailed thermodynamic insight into the total binding energy, the binding energies 
were further decomposed into individual residue contributions and are shown in Figure: 4.8. The 
decomposition of binding energy per residue constitutes ΔEvdw, ΔEelec, ΔEpolar and ΔEnon-polar. It is 
revealed that, in Mode-1 and Mode-2/hydrophobic, the binding energy contribution is distributed 
amongst several residues of the core region (Phe19, Leu17, Lys28, Lue34, Val36); in the case of 
Mode-2/lys28 and Mode-3/lys16, however, the only significant binders are Lys28 and Lys16. In 
Mode-1, Asp23, Val24 and Mode-2 (hydrophobic and Lys28) the negatively charged Asp23 has 




      
Figure: 4.8 A) Residue contributions to binding energy in Mode-1/ hydrophobic (U-shaped structure opening). 
B) Residue contributions to binding energy in Mode-2/hydrophobic (Tug of war). C)  Residue contributions to 
binding energy of Mode-2/Lys28 (Tug of War). D) Residue contributions to binding energy of Mode-3/Lys16. 
 
4.4 Perspective and concluding remarks 
Similar binding modes were observed, experimentally and theoretically,  for 18-crown-6 with several 
proteins (but not Aβ fibrils).
10
.  The crown ether specially interacts with hydrophobic patches forming 
Van der Waals interactions with aromatic or aliphatic residues.  Moreover, binding between the crown 
and a single Lys or Lys in the vicinity of hydrophobic residues was observed.  Our data also supports 
the hypothesis by Tian et. al.
9
 that 12-crown-4 can form hydrogen bonds with positively charged 
residues, especially with Lys16 and Lys28, and destabilizes the salt-bridges formed by these residues.  
Various studies have shown that the salt-bridge between Asp23-Lys28 plays a crucial role in structure 
stability and cytotoxicity
20,21,22
.  Other experimentally known, structurally distinct inhibitor molecules, 
such as Congo red, Naproxen, Ibuprofen, and Curcumin are shown to bind to Lys28 using docking 
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and MD simulations studies
23,24
.  The salt-bridge formed between Lys16-Glu22 plays an important 
role in stabilizing the structure of Aβ fibrils in antiparallel arrangement.  If the 12-crown-4 binds to 
Lys16, it could destabilize such antiparallel Aβ fibrils. 
Many studies have shown that side-chain interlocking of hydrophobic residues in the core region play 
a crucial role in  the U-shaped structure stability
25,26,27
.  In particular Chandrakesan et al.
12
,  showed 
that contact between  Phe19 and Leu34 is crucial for Aβ fibrils formation and suggested that  Phe19 
and Lue34 provides considerable stabilization for aggregation; the authors proposed that disrupting  
the contact between Phe19 and Leu34 is expected to have a very strong effect on the aggregation of 
Aβ fibrils. A study by  Das et al. showed that contact between Phe19 and Leu34 plays an important 
role in Aβ40 oligomer cytotoxicity
11
.  Control simulation data in the present study (Aβ40 fibril trimer 
in absence of 12-crown-4) revealed that the Aβ40 fibril trimer maintained hydrophobic side-chain 
contact in the core region in all simulation trajectories; this helped it to retain its U-shaped topology. 
A  MD simulation study by  Buchete et al 
28
 suggested that hydrophobic interactions, stabilizing the 
C-terminal β-sheet, play a crucial role in the elongation of Aβ fibril.  A study by Horn et al. 
29
 
revealed that the Aβ trimer is the smallest unit that can maintain the U-shaped structure and is a 
potential seed for fibril elongation.  It should, therefore, be considered that a disruption of these 
hydrophobic interactions and the U-shaped structure, as observed in the present study, could indeed 
affect elongation.   Taken together all these data, we propose that 12-crown-4 binding to hydrophobic 
core residues (Phe19, Leu34) and positively charged Lys16, Lys28 could significantly reduce the 
cytotoxicity, structure stability and the elongation process. 
Studies on oral toxicity of 12-crown-4 in mice and rats showed that 12-crown-4 had median lethal 
dose (LD50) values of 3.15 grams/ Kg and 2.8 grams/Kg, respectively
30,31
.  A further dermal toxicity 
study in rabbits revealed that the LD50 value was 4.5 grams/Kg
32
.  Since different organisms have been 
used in testing the toxicity, without further studies, it would be difficult to generalize 12-crown-4 
toxicity.  This study, however, has shown the chemical features that could be required to design an 
effective Aβ fibril inhibitor; that is, 12-crown-4 contains both hydrophilic oxygen atoms and 
hydrophobic hydrocarbon groups. 
In summary, we have studied the effect of 12-crown-4 on Aβ40 fibril trimer by performing 
simulations in the presence and absence of 12-crown-4; we observed three possible binding modes of 
12-crown-4 on Aβ40 fibril.  First, the 12-crown-4 can enter into the hydrophobic core and interact 
with hydrophobic residues by Van der Waals interactions; when this occurs there is a disruption of the 
hydrophobic interactions between two β-sheets and this leads to the opening of the U-shaped structure 
and drastic conversion of β-sheet into random coil and α-helix.  The second mode involves a “tug of 
war”, where the 12-crown-4 enters into the hydrophobic core but instead of causing an opening event, 
it subsequently moves towards the Asp23-Lys28 salt bridge, causing it to break. Lastly, there is 
significant binding of 12-crown-4 with Lys16, which is implicated in stabilizing the structure of Aβ 
fibrils in antiparallel arrangement. The present study deepens our knowledge of how a candidate 
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molecule can remodel Aβ40 fibril and provides information that can be used in the design of new, 
potential drugs; therefore, provides new avenues for Aβ40 fibril inhibition. 
 
4.5 Methods 
4.5.1 12-crown-4 ether structure and force field 
The 12-crown-4 is a cyclic ether molecule  and the coordinate for 12-crown-4 ether was taken from 
PubChem compound library (CID: 9269)
33
.  The force field parameters of 12-crown-4 ether molecule 
were derived from the  Charmm Additive and Classical Drude Polarizable Force Fields for Linear and 
Cyclic Ethers (ACDPFF)
34
.  Parameters for 12-crown-4 cyclic ether are provided in Table: 4.2S). 
4.5.2 Simulation protocol 
All simulations were performed using the GROMACS 4.6.3
35
 molecular dynamics program. The 
Charmm36 force field
36
  was used for the Aβ40 fibril trimer, which were solvated using the TIP3P 
water model
37
. Systems of Aβ40 fibril with 12-crown-4 contain 22518 water molecules and systems 
of the Aβ40 fibril, in the absence of 12-crown-4, contain 18347 water molecules.  Nine Na
+ 
counter 
ions were added to neutralize the systems. All systems were energy minimized using 5000 steepest 
descent steps
38
. The systems were then equilibrated for 100 ps using the cononical (NVT) ensemble, 
followed by a further 100 ps of equilibration simulation with the isobaric-isothermic (NPT) ensemble. 
The production run for all systems were performed in the NPT ensemble.  The LINCS
39
 algorithm 
was used to constrain the hydrogen bond lengths of the Aβ40 fibril and 12-crown-4 molecule. Water 
molecule bond lengths were constrained with the SETTLE
40
 algorithm, which allowed an integration 
time step of 2 fs.  Long-range electrostatic interactions were calculated using the particle mesh Ewald 
(PME)
41
 method with a real space cut-off of 1.2 nm. The van der Waals (vdW) interactions were 
calculated using a cut off of 1.2 nm. The Aβ40 fibril was separately coupled to the external 
temperature and pressure baths and the non-protein components, 12-crown-4, water and ions were 





 methods. All MD simulations were performed at a temperature of 310 K and a 




Set I: Control Aβ40 trimer simulations  
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To explore the inherent conformational changes, and to check the stability of the U-shaped topology 
in the absence of 12-crown-4, two sets of control simulations were performed, three long (500 ns) and 
five short simulations (100 ns) using random initial velocities.  
Set II. Aβ40 trimer with 12-crown-4  
The 12-crown-4 and Aβ40 fibril systems consist of an Aβ40 fibril trimer and six 12-crown-4 
molecules randomly placed at a minimum distance of 12 Å from the trimer (Figure: 4.1C). The 
systems were prepared as described previously and an additional six 12-crown-4 molecules were 
added before solvating the system. 15 simulations were performed with random initial velocities and 
the simulation time was different for all trajectories.  In our simulations we did not apply any 
restraints or prior contact between Aβ40 fibril and 12-crown-4 molecule. 
4.5.3 Analysis details 
Interaction and binding energies between the Aβ40 fibril and the 12-crown-4 was calculated using 
Molecular Mechanics–Poisson Boltzmann Surface Area (MM-PBSA), implemented in g_mmpbsa 
package
44
. The structural stability of the trimer was measured by root-mean-square deviation (RMSD) 
of the backbone atoms, of residues 11-40, with respect to the energy minimized structure. “Opening” 
of the U-shaped topology was defined by the centre of mass (COM) distance between residue 16- 20 
(top β-sheet) and residue 33-40 (bottom β-sheet) of all three peptides (Figure: 4.9A).  Entering of 12-
crown-4 inside the core region is defined by COM distance between 12-crown-4 and residues 16-36 





Figure: 4.9 A) Centre of mass (COM) of Residues 16-20 and COM of Residues 33-40. B) COM of Residues 16-
36.  
4.6 Supporting Information 
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The Supporting Information is available free of charge on the ACS Publications website at DOI: 
10.1021/acschemneuro. 6b00185. 
Results for control simulations (500 ns), entering and opening of two other trajectories, displacement 
of water molecules upon binding, and force field parameters for 
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Alzheimer's disease is the most common form of dementia characterized by misfolding and 
aggregation of amyloid-β (Aβ) peptides into β-sheet rich Aβ oligomers/fibrils. Experimental studies 
have suggested that Aβ oligomers/fibrils interact with the neuronal cell membranes and perturb their 
structures and dynamics. However, the molecular mechanism of Aβ oligomers/fibrils interaction with 
the neuronal membranes remained elusive. In present work, we have performed more than 8 μs 
simulations of Aβ9-40 fibrils hexamer with cholesterol-rich DPPC bilayer, which are the most abundant 
lipids in the neuronal membrane. Our simulation data reveals spontaneous insertion of aqueous Aβ9-40 
fibrils hexamer into the membrane and the central hydrophobic cluster and C-terminal hydrophobic 
residues plays a crucial role in the insertion process. Due to the hydrophobic nature of binding 
residues, VdWs interactions are more dominant than the electrostatic interactions. A decrease in the 
number of water molecules around Aβ9-40 fibrils and loss of conformation entropy in chain B is 
observed as the distance between Aβ9-40 fibrils and membrane decreases. We further observe that the 
binding of Aβ9-40 fibrils causes the localized thinning of the membrane at the point of insertion. The 
identified binding residues of Aβ fibrils could sever as a potential target region to design new 
inhibitors, thus open new avenues in structure-based drug design for Aβ oligomer/fibrils membrane 
interaction inhibitors.   
  





5.2 Introduction  
Amyloid fibrils are misfolded β-sheet rich aggregated proteins, which play a key role in over 20 
disease conditions that include Alzheimer’s disease (AD), Parkinson’s disease (PD), type 2 diabetes 
and different forms of systemic amyloidosis
1-4
.  Disease conditions involving amyloid formation are 
commonly known as protein misfolding diseases, which affect more than 500 million people in the 
world
2
.  According to the Amyloid cascade hypothesis in the AD, the amyloid βeta peptide (Aβ) 
undergoes conformational changes to form water-insoluble Aβ fibrils in the brain of AD patient
5
. 
These Aβ fibrils then form extracellular neuronal plaques, which have been suggested as the major 
pathological hallmark of AD
6
. 
   Toxicity of Alzheimer’s Aβ is still not completely understood; however, several mechanisms 
have been proposed to explain it; these are 1) Aβ monomer itself is neurotoxic, or Aβ monomer at 
higher concertation are neurotoxic
7-8
 2) Aβ aggregate/oligomers interact with membranes and increase 
membrane permeability
9
.  3) Aβ oligomers form ion channels in the membrane that disrupt the 




. 4) Membrane lipids can convert inert Aβ fibrils into neurotoxic 
protofibrils
11
. Most of these studies have highlighted that Aβ binding with membrane lipids leads to 
neurotoxicity.  
          Various studies have been performed using different experimental techniques to reveal the 
interaction of Aβ fibrils with lipids. A recent study by Han et al.12,  using the Electron tomography 
technique revealed that Aβ fibrils interaction with lipids of different sizes and their work further 
revealed that intracellular fibrils deform the structure of intracellular lipid vesicles and puncture 
through the vesicular membrane into the cytoplasm.  Kiskis et al.
13
, using simultaneous coherent anti-
Stokes Raman scattering (CARS) and 2-photon fluorescence microscopy of Thioflavin-S techniques 
showed that lipids co-localize with fibrillar β-amyloid (Aβ) plaques. In another study, Burns et al.
14
 
experimental study revealed co-localization of cholesterol in Aβ plaques. Ji et al.15  revealed the role 
of cholesterol concentration on the Aβ1-40 insertion in the membrane and secondary structure. They 
prepared dipalmitoylphosphatidylcholine (DPPC) monolayer with 20, 25, 33, 56, and 74 mol% 
cholesterol, respectively; their data suggested that Aβ1-40 can only able to insert into the membrane 
when the cholesterol content was greater than 30%. Their results further suggested that at the low 
concentration of cholesterol (30% or less) Aβ prefers to stay on membrane surface in the β-sheet 
conformation.  
Previously, several MD simulations studies have been performed on the interaction between 
membranes and Aβ oligomers/fibrils; for example, Yu et al.16  performed MD simulations  of Aβ17-42 
fibrils with mixed anionic POPC–POPG bilayer. Their data revealed that anionic lipids help the 
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absorption of Aβ17-42 pentamer in the membrane and Ca
+
 mediate negatively charged residues Glu22 
and Aps23 interactions with phosphate head groups. Tofoleanu
17
 et al.  conducted Aβ fibrils MD 
simulations with POPE lipid bilayer, and their data revealed that charged residues Glu22, Aps23 and 
Lys28 form electrostatic interactions with head group atoms. In another study, Tofoleanu
18
 performed 
MD simulations of Aβ fibrils with POPC and POPE bilayers and revealed that Aβ fibrils formed 
short-lived contacts with POPC headgroups and strong contacts with POPE headgroups and suggested 
the interaction of Aβ fibrils oligomers with membranes would be more notorious in case of the 
biological condition in the presence of cholesterol. In a recent work Dong et al.
19
 performed MD 
simulations of Aβ9-40 fibrils trimers with POPG bilayer and revealed that N-terminal β-sheet forms 
contact with POPG bilayer. In all the aforementioned studies, Aβ fibrils were placed near to the 
membrane, and to best of our knowledge, no previous MD simulation study has been performed to 
investigate Aβ fibrils in contact with a lipid bilayer consisting of cholesterol lipids, which is one of 
the most important contents of the neuronal cell membranes
20
.  
In the present study, we aim to capture spontaneous insertion of Aβ9-40 fibrils hexamer in the DPPC 
and Cholesterol mixed bilayer. To fulfill this aim, we have performed 4 Coarse-grained MD 
simulations, for more than 8 μs. The MD study will allow us to answer the following questions: 1) 
Does Aβ fibrils oligomer spontaneously insert inside the bilayer? 2) Which region of Aβ fibrils binds 
with the membrane? 3) What kinds of interactions dominate Aβ fibrils interactions with membrane 
VdW or electrostatics? 4) What is the role of water molecules in Aβ fibrils interaction with 
membrane? 5) Does the binding of Aβ fibrils affect the thickness of the bilayer?  
5.3 Methods  
5.3.1 Structure and force field of Aβ9-40 hexamer fibrils initial structure 
 
In the present study, coarse-grained molecular dynamics simulations were performed where the 
NMR-derived Aβ9-40 fibrils hexamer (PDB id: 2LMN) single layer was taken from two-fold symmetry 
structure. Aβ9-40 fibrils structure contains two β-sheets (residue 13-19 and residue 32-40)
21
. The 
atomistic structure (Figure: 5.1A) was converted into the CG model (Figure: 5.1B) using the 
CHARMM-GUI Martini maker
22, 23
. Martini2.2 force field
24





Figure: 5.1 A) Shows NMR structure of Aβ9-40 fibrils (PDB id: 2LMN).   B) Shows the CG model of Aβ9-40 
fibrils. C) Shows cholesterol mixed DPPC bilayer. 
5.3.2 Structure and force field parameters for the DPPC-Cholesterol membrane  
It has been reported that in neuronal cells, membrane lipids are not randomly distributed, instead form 
lipid domains, where sphingolipids and cholesterol are segregated in DPPC rich membrane areas
25
. In 
the present study, we have used ~70.37% DPPC and ~29.63% cholesterol as used in the experimental 
study by Ji et al.
15
. The initial structure of DPPC-cholesterol was downloaded from CG martini 
website
26
 and to make the larger patch of the membrane it was replicated in x and y-direction. The 
larger patch of bilayer contains 1368 DPPC molecules and 576 cholesterol molecules (Figure: 5.1C); 
the structure was equilibrated for 15 ns before being used for MD simulations with Aβ9-40 fibrils. 
Martini 2.0 force field parameters were used for the membrane and water. 
5.3.3 Simulation protocol 
The system contains one Aβ9-40 hexamer, DPPC-cholesterol bilayer, and 107194 water molecules. To 
neutralize the system 6 Na
+
 ions were added. Initially, 5000 steps of steepest descent
27
 were 
performed to energy minimize the systems, followed by 30 ns equilibration using canonical ensemble 
(NVT) followed by 100ns equilibration using the isobaric-isothermal ensemble (NPT). The 
production run was performed using the NPT ensemble.  The Berendsen algorithm
28
 was used for 
pressure coupling and velocity-rescale algorithm
29
 was used for temperature coupling. Pressure 
coupling and temperature bath times were set 5.0 and 1.0 ps, respectively. All simulations were 
performed at a temperature of 303.15K and 1 atm pressure. The Particle mesh Ewald (PME) 
algorithm
30
 was used for long-range electrostatic interactions and van der Waals (vdW) interactions 
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were calculated using the switch function from 9 to 12 Å; 20 fs time step was used for integration of 
Newton’s equations of motion.  
 A total of 4 simulations were performed using initial random velocity generated by the 
GROMACS
31
. Each trajectory simulation time was more than 2 μs. 
5.3.4 Analysis details 
The centre of mass (COM) distances in Z-dimension was calculated between each chain of the Aβ9-40 
fibrils and PO4 groups of upper-leaflet of the membrane using an in-house Tcl script. The interaction 
energy between Aβ9-40 fibrils each chain with the membrane was calculated using GROMACS 
MDRUN program using “rerun” option. An interaction between Aβ9-40 fibrils residues was considered 
when the distance between COM of residues and COM of membrane lipids (DPPC/cholesterol) was 
10 Å or less. The percentage of contacts of the Aβ9-40 fibrils and chain B was calculated by counting 
the number of times an interaction occurred. The number of water molecules has been calculated 
within 5Å and number of DPPC and cholesterol within 10Å using in-house Tcl script. The bilayer 
thickness was calculated using g_thickness
32
 tool for different time point’s average over 100ns. The 
thickness was calculated using the distance between two PO4 head groups of upper and lower leaflets 
of the membrane. To investigate the conformational entropy of chain B of Aβ9-40 fibrils the mass-




5.4 Results  
5.4.1 Insertion of Aβ9-40 fibrils chains inside membrane  
Out of a total 4 independent trajectories, we observed insertion of Aβ9-40 fibrils chains in two 
trajectories. In the other two trajectories, we observed transient contacts between Aβ9-40 fibrils and 
membrane. Figure: 5.2A shows the time evolution of the centre of mass distance between each chain 
with upper leaflet PO4 beads. Figure: 5.2B shows the time evolution of interaction energy between 
membranes (DPPC/CHO). The stepwise process of the spontaneous insertion of Aβ9-40 fibrils has been 
shown in Figure: 5.3. Insertion of Aβ9-40 fibrils in mixed lipids bilayer took places in sequential steps:  
in step A ~400 ns the protein came near to the membrane, as shown by a decrease in the distances of 
each chain from the PO4 beads; however, Aβ9-40 fibrils does not form any contact with the membrane 
at this time. In step B at ~500ns, Aβ9-40 fibrils reoriented and Chain B and Chain C form contacts with 
the membrane, as shown by a further decrease in distances of Chain B and Chain C from the PO4 
beads (Figure: 5.2A red and green lines), during this time, the interaction energy between chain B and 
the membrane  was  ~-700 kJ/mol and chain C and the membrane was ~-473 kJ/mol. In step-c 





until the end of simulation. To understand what kind of interactions drive the binding of Aβ 
fibrils with the membrane, we further calculated non-bonded interaction energy components between 
Chain B, Chain C and the membrane. Energy decomposition revealed that VdW interaction is more 




  Figure: 5.2 A) Shows time evolution of centre of mass (COM) distance between each chains of Aβfibril9-40 
from   COM of PO4 bead of upper leaflet. B) Shows the time evolution of interaction energy between Aβfibril9-
40 each chain from the membrane. C) Shows the electrostatic interaction between chain B and C with membrane. 





Figure: 5.3 Shows structures of Aβ9-40 fibrils at four different time points taken from the representative 
trajectory. A) Shows representative image at 100 ns. B) Shows representative image at 400 ns. C) Shows 
representative image at 1200 ns (1.2 μs). D) Shows representative image at 2000 ns (2μs).  Each chain of protein 
has been shown in different colour, Chain A silver, Chain B red, Chain C green, Chain D blue, Chain E ochre 
and Chain F in purple. Protein beads are represented in VdW and membrane in Licorice. DPPC lipid molecules 
have been shown in cyan colour and cholesterol lipid molecules have been shown in maroon.  
5.4.2 Percentage of contacts  
To identify chain B residues that more strongly bind with the upper leaflet and, therefore, assist Aβ 
fibrils insertion into the membrane, we have calculated the percentage of contacts of each residue of 
Chain B with PO4 beads of DPPC and ROH beads of cholesterol. Figure: 5.4B shows the percentage 
of contacts formed by Chain B residues with PO4 beads. We observed central hydrophobic cluster 
(CHC) residues Lys16, Leu17, Val18, Phe19 and Phe20 (Aβ16-20), turn region residues Gly29 and 
Ala30 and second β-sheet residues (32-40) form major contacts with the membrane. This could be 
significant since the binding of Aβ fibrils with the membrane was governed by VdW’s rather than 
electrostatic interactions.   The CHC region and turn region residues have been previously reported to 




 et al. experimental study revealed that Aβ 




Figure: 5.4 A) Shows Aβ9-40 fibrils binding with the membrane. Protein has been shown in ice blue colour with 
surf representation and chain B and Chain C have been shown in red and green colours, respectively.  PO4 and 
ROH beads have been shown in VdW representation in orange and maroon colour.  B) Shows percentage of 
contacts of graph of Chain B with DPPC and Cholesterol lipids and CHC region and C-terminal residues have 
been shown in circles. D) Shows the major binding residues of Chain B on atomistic model. 
5.4.3 Time evolution of number of water, lipid molecules around Aβ9-40 fibrils and change in 
the conformational entropy 
To investigate how many water molecules Aβ9-40 fibrils have to displace to interact with the 
membrane, we calculated the time evolution of the number of water molecules within 5Å of Aβ9-40 
fibril (Figure: 5.5A). We observed that, as the distance of Aβ9-40 fibrils decreases from the membrane, 
the number of water molecules also decreases.  In the beginning (0 to 450 ns), before Aβ fibrils form 
interactions with the membrane there were  ~164  ± 11.3 water molecules around Aβ9-40 fibrils, which 
decreased to ~142.5 ± 9.5, during the period from 500 ns to 1.3 μs, when Aβ9-40 fibrils established 
interactions with the membrane. A further displacement of water molecules was observed ~1.3 μs, 
when Aβ9-40 fibrils inserted deeply inside the membrane. On average there were ~131 ± 8.8 water 
molecules around Aβ9-40 fibrils during the period from 1.3 μs to 2.15 μs. Overall, aqueous phase Aβ9-40 
fibrils have to displace ~33 water molecules to insert into the cholesterol-rich DPPC membrane.  
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To investigate the number of lipids molecules around Aβ9-40 fibrils, we calculated the time 
evolution of DPPC and cholesterol lipid molecules within 10 Å of Aβ9-40 fibrils (Figure: 5.5B). 
During 0 to 450 ns, before Aβ fibrils formed interactions with the membrane, we observed on average 
0 DPPC lipid molecules and 0 cholesterol lipid molecules. The number of lipid molecules around Aβ9-
40 fibrils increased in two phases in the first phase during the period from 500 ns to 1.3 μs, when Aβ9-
40 fibrils established the interactions with the membrane, there were on average ~16.6 ± 3.8 DPPC 
molecules and ~5.01 ± 2.03 cholesterol molecules around Aβ9-40 fibrils. In the second phase, when 
Aβ9-40 fibrils inserted deeply inside the membrane; during 1.3 μs to 2.15 μs, there were on average 
~16.9 ± 3.5 DPPC lipid molecules and ~6.45 ± 1.6 cholesterol lipid molecules around Aβ9-40 fibrils. A 
significant gain of ~1.44 cholesterol molecules during the second phase indicates that cholesterol 
lipids play a crucial role in the insertion of Aβ9-40 fibrils in the membrane. 
       
Figure: 5.5 A) Shows the time evolution of number of water molecules around the Aβ9-40 fibrils. B) Shows the 
time evolution of number of DPPC and cholesterol lipid molecules around the Aβ9-40 fibrils. C) Show the change 
in conformation entropy of chain B and C with respect to the time. D) Shows the water molecules on surface of 
Aβ9-40 fibrils at two different time point. Protein has been shown in white in surf representation and residues 
with 10Å of the membrane have been shown in blue color. Water has been shown in VdW representation in red 
color.  
The time evolution of change in the conformational entropy of the membrane binding chain B 
(Figure: 5.5C) revealed that conformation entropy of chain B decreased as the number of water 
molecules decreased or the number of lipids molecules increased around Aβ9-40 fibrils. Change in 
conformation entropy of chain B can be divided into three stages, the first stage was from 0 to 450 ns, 
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before the Aβ9-40 fibrils formed interactions with the membrane. The second stage (500 ns to 1.3 μs) 
was when Aβ9-40 fibrils established interactions with the membrane, and the third stage, when it deeply 
inserted inside the membrane (1.3 μs to 2.15 μs). In the first phase on average conformation entropy 
of chain B was ~2925.87 ± 634.54, in the second phase ~2892.45 ± 88.31 and in the third phase 




, respectively. This result revealed that chain B has high conformational 
entropy in aqueous environment compare to the membrane environment. It could be significant since 
water molecules are mobile than lipid molecules. Also, the loss of entropy must be offset by the 
interaction between chain B and the membrane (Figure: 5.2D). 
5.4.4 Perturbation of thickness of bilayer  
To investigate the effect of binding of Aβ9-40 fibril on the membrane, we have calculated the thickness 
of the membrane before (300 ns to 400 ns) and after binding (1.7 μs to 1.8 μs) of the Aβ9-40 fibrils. On 
average, the thickness of the bilayer before Aβ9-40 fibrils insertion throughout the box was uniform 
(Figure: 5.6A). However, after the insertion of Aβ9-40 fibrils, localized thinning in the region of 
insertion was observed. (Figure: 5.6B). These results revealed that Aβ9-40 fibrils binding affected the 
local lipid distribution in the membrane, which leads to thinning in one region and increased thickness 
in the rest of the membrane. Previous experimental studies have revealed that peptide/protein binding 
on the surface membrane cause membrane thinning, which is directly dependent on the concentration 
of the peptide
35, 36
. Insertion of the peptides inside the membrane could lead to the formation of pores 
in the membrane
35, 37
. Our results revealed that binding of a single molecule of Aβ fibril (6 peptides) 
lead to the localized thinning in the membrane; however, in-vivo, the number of Aβ peptides, which 
interact with the membrane, could be greater causing significantly thinning of the membrane, which 
could lead to further pore formation in the membrane.    
 
Figure: 5.6A) Shows the thickness of the membrane during 300-400 ns b) Shows the thickness of the membrane 




Aβ protein interaction with the membranes plays a key role in the toxicity of Alzheimer’s and 
cholesterol lipids have been reported to play an important role in Aβ protein interaction with the 
membrane
38, 39
. Computer simulations have helped to reveal the molecular details of Aβ proteins 
interaction with candidate drug molecules and biological membranes
40-42
. In the present study, we 
have performed Aβ9-40 simulations with cholesterol-rich DPPC bilayer. In all previous studies, 
simulations of Aβ proteins begin from a membrane-bound conformation, and therefore, details key 
transition events such as membrane binding remains elusive. In the present work, we have revealed 
the spontaneous insertion of aqueous phase Aβ9-40 fibrils into the cholesterol-rich DPPC membrane 
using more than 8 μs long simulations at physiological temperature.  
   Our simulation data reveals that CHC region and second β-sheet residues of Aβ9-40 fibrils 
forms major contacts with the membrane. CHC region residues have been previously reported to 
make interaction with membrane
34
 and also been reported to play a key role in aggregation of Aβ 
peptides
43
. The present simulations data revealed that Aβ9-40 fibrils interaction with the membrane is 
majorly governed by the hydrophobic residues and to form the interaction with the membrane Aβ9-40 
fibrils rearranged itself so that hydrophobic residues face to the membrane. We also observed a loss of 
water molecules and increase in the number of lipid molecules around chain B, which leads to a 
significant loss of conformation entropy of chain B and may play a crucial role in the binding of Aβ9-
40 fibrils to the membrane. Our data is also in agreement with the previous studies
44, 45
, which 
suggested that cholesterol promotes Aβ interaction with the membrane; we observed that after 
insertion into the membrane, the interaction between Aβ fibrils and cholesterol molecules increases. 
At the position where Aβ9-40 fibrils inserted, the thickness was locally decreased; in this way, Aβ 
fibril/aggregate could lead to the formation of a pore, which would disrupt the membrane and result in 
neuronal cytotoxicity.    
5.6 Conclusions 
In summary, our simulations have shed light on the fundamental understating Aβ fibrils interaction 
with the membrane. Our simulation data revealed spontaneous insertion of aqueous Aβ9-40 fibrils in 
cholesterols-rich DPPC bilayer. To the best of our knowledge, this is the first report to show 
spontaneous insertion of Aβ fibrils using the most abundant lipid molecules in the neuronal cell 
membrane. Our simulation revealed the key binding residues, which stabilized the interaction of Aβ 
fibril. Our simulation data further revealed loss in the conformational entropy of membrane binding 
chain of Aβ9-40 fibrils as the number of water molecules decreased around Aβ9-40 fibrils. The identified 
Aβ9-40 fibrils residues of CHC region and second β-sheet could be used as a target site to design new 
candidate drug molecules, which could inhibit its association with the membrane, and further stop the 
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CONCLUSIONS AND FUTURE PERSPECTIVE 
 
Toxicity of Aβ peptides is still not completely understood; however, various mechanisms have been 
proposed to explain it; these are 1) Aβ monomers are toxic, 2) Aβ fibrils are toxic 3) Aβ fibrils 
interaction with membrane lipids leads to toxicity. Experimental studies have demonstrated that 
perturbing the Aβ monomers misfolding, disrupting the Aβ fibrils structure, and inhibiting the Aβ 
fibrils interactions with the membrane could reduce toxicity caused by them.   
The body of work assembled here sought to explore binding of 12-crown-4, with Aβ1-40, 
Aβ1-42 monomers and Aβ1-40 fibril and binding of Aβ9-40 hexamer fibrils with cholesterol-rich 
DPPC bilayer.  This overall aim of the present thesis was to identify the key pharmacophore features 
required in candidate drug molecule to bind with Aβ monomer, Aβ fibrils, and the key 
pharmacophore features of Aβ fibrils that requited it to bind with the most abundant lipids of neuronal 
cell membrane.  Identification of these pharmacophore features will help to design the new candidate 
drug molecule, which could reduce toxicity caused by Aβ monomers and fibrils.  To achieve our aims 
we have conducted all-atom MD simulations of Aβ1-40 and Aβ1-42 monomers and Aβ1-40 fibrils in 
the presence and absence of 12-crown-4 and CG MD simulations of Aβ9-40 fibrils hexamer with 
 Simulations of Aβ1-40 and Aβ1-42 monomers with 12-crown-4 shows that the molecule is 
highly specific toward positively charged Lys residues and the region around Val24-Lys28 is most 
prevalent for turn formation. Simulations results of Aβ1-40 fibril trimer with 12-crown-4 simulations 
reveals that it spontaneously, inserted into the hydrophobic core and opened the “U-shaped” topology 
of Aβ fibrils trimer and also disrupted Lys28-Asp23 salt bridge. Aβ fibrils hexamer with cholesterol-
rich DPPC bilayer simulations reveals that Aβ9-40 fibrils hexamer spontaneously inserted to the mixed 
bilayer and hydrophobic residues played a key role in its binding, especially central hydrophobic 
cluster region (Lys16-Phe20) and C-terminal residues (Ile32-Val40). Insertion of Aβ9-40 fibrils 
hexamer leads to localized thinning of the membrane.  
Results of Aβ monomers and Aβ fibrils trimer with 12-crown-4 ether reveals key 
pharmacophore features required in molecules to specifically bind with Aβ peptides. Data of Aβ 
fibrils hexamer identifies key pharmacophore features of Aβ protein to bind with the mixed lipid 
bilayer. The identified pharmacophore features will not only help in designing new candidate drug 
molecules, which are specific to Aβ peptides but could also be used to design new imaging probe 
molecules for labeling Aβ peptides. 
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